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Abstract 
Previous research relating to Alpha-GPC supplementation and physical performance has 
been limited to researching Alpha-GPC as a single ingredient supplement. Further research 
is needed to investigate the effect of Alpha-GPC in combination with other ergogenic 
ingredients on physical performance. Purpose: The purpose of this study was to investigate 
the acute effect of Myosync™ on physical performance in Division II football players. 
Methods: Fourteen male Division II football players (20.4 ± 1.0 years; 191.4 ± 5.5 cm; 
106.9 ± 16.4 kg) participated in a randomized double blind crossover experiment separated 
by at least seven days. Subjects were given Myosync™ (2 Capsules, 1,076 mg) or a placebo 
control (2 capsules of fiber) 60 minutes prior to any physical testing measures. Testing 
consisted of, maximum vertical jumps, maximum voluntary isometric contractions 
(MVIC), maximal voluntary concentric contractions (MVCC), and fatiguing contractions 
for the knee extensor muscles. Subjects performed three maximum vertical jumps with 
one-minute rest between jumps. Three MVICs were performed with the knee extensor 
muscles while seated on a dynamometer at 90° of hip flexion and knee flexion, with 2-
minute rest between trials.  Seven sets of two MVCCs at various loads (1 Nm; 10%, 20%, 
30%, 40%, 50% and 60% MVIC torque) were completed with 30-seconds of rest between 
each set. During the fatiguing tasks, 120 MVCCs (4 set x 30 reps) were performed with a 
load equivalent to 20% MVIC through 60 degree range of motion.  Recovery measures 
were taken 10 minutes post completion of fatiguing task and consisted of one MVIC and 
MVCCs using the same loads as pre-fatiguing task. Results: There was no difference in 
maximum vertical  jump height between control and supplemental sessions (70.8 ± 6.6 vs 
70.9 ± 6.2 cm, P = 0.90). MVIC was similar between control and supplemental sessions at 
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baseline (297.8± 48.4 vs. 296.7 ± 70.5 Nm, respectively, P = 0.34). Rate of torque 
development (highest slope of torque during the first 400 ms during MVIC was 
significantly higher throughout the fatiguing task during the supplemental session (P = 
0.02). Impulse for all MVIC significantly increased at 200 ms throughout the fatiguing task 
during the supplemental session (P < 0.001). No significant differences seen between peak 
power during isotonic contractions as well as fatigability between sessions. Conclusion: 
Maximal strength, power and vertical jump did not improve with Myosync™, however, 
the significant increases in rate of torque development and impulse could be beneficial for 
a variety of athletes. 
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1.  INTRODUCTION 
 Introduction 
With the highly competitive culture in today’s athletics, some athletes may look to 
supplementation as a means of gaining a physical edge on their competition (Lavallee, 
2012). Most nutritional ergogenic aids are used to enhance energy metabolism during sport 
performance by either providing an additional source of energy, or favorably affecting 
metabolic processes that generate energy (Kanter & Williams, 1995). When discussing the 
topic of supplementation, many products are included such as, protein, creatine, 
androstenedione, hormone precursors and other stimulants. Over 500 clients were given a 
one page questionnaire to assess the use of various supplements (Kanayama, Gruber, Pope, 
Borowiecki, & Hudson, 2001) and  of 334 males that responded, 61% used a protein 
supplement, 47% used creatine, and 4% admitted to using androstenedione for 6 months 
or longer.   
The regulation of supplementation is the responsibility of the Food and Drug 
Administration (FDA) as well as the Federal Trade Commission (FTC) (Fomous, Costello, 
& Coates, 2002). Separate from the FDA and FTC regulations, various governing bodies 
over athletics such as the NCAA have their own set of banned substances. Every four years 
the NCAA distributes a survey to student athletes in attempt to evaluate the use of 
supplementation in college athletics (Green, Uryasz, Petr, & Bray, 2001). Through this 
2001 survey, the NCAA was able to determine that the most popular supplement that was 
used in college athletics was creatine (29%). The study also uncovered that the most 
common reason for athletes using supplementation was to improve performance and 
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physical appearance. It is the position of the Academy of Nutrition and Dietetics, Dietitians 
of Canada, along with the American College of Sports Medicine that performance of, and 
recovery from sporting activities are enhanced by well-chosen nutrition strategies along 
with proper supplementation (Thomas, Erdman, & Burke, 2016).  
One of the most popular types of supplementation among athletes at the collegiate 
level are various pre-workout supplements taken with hopes to improve performance in 
either training sessions or competitions. A main ingredient in many pre-workout 
supplements is caffeine, due to its ergogenic effect of decreasing the perception of fatigue 
while exercising (Astorino & Roberson, 2010). Although caffeine, when taken in the 
proper dose has been shown to provide benefits for exercising, it is also important to note 
that when too much caffeine is supplemented, adverse side effects such as tremors and 
increased anxiety and large doses of caffeine can be toxic (Tarnopolsky, 2010). Other 
common yet often overlooked pre-workout supplements include the various over the 
counter energy drinks that are used. It was discovered through a survey conducted at a 
Division I university that the most common nutritional supplement taken by athletes was 
energy drinks  (Froiland, Koszewski, Hingst, & Kopecky, 2004).  
Beta-Alanine is another common supplementation taken by athletes before exercise 
or competition. Beta-Alanine can be used as a single ingredient supplement, or it may be 
one of many ingredients included in a proprietary blend that makes up a pre-workout 
supplement. Through a review of the literature pertaining to Beta-Alanine 
supplementation, Quesnele, Laframboise, Wong, Kim, and Wells (2014) found that Beta-
Alanine supplementation was mostly targeted for events that are associated with a high rate 
of anaerobic glycolysis (i.e., events lasting ~60-240 seconds). It was also found through 
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the same review that chronic Beta-Alanine supplementation can significantly increase 
muscle carnosine (Quesnele et al., 2014).  
A specific type of supplement that is of interest is choline supplementation. Various 
studies have investigated the effects of both acute and chronic choline supplementation on 
physical performance (Bellar, LeBlanc, & Campbell, 2015; P. A. Deuster, Singh, Coll, 
Hyde, & Becker, 2002; Warber et al., 2000). Studies have investigated the effects of 
choline supplementation on prolonged exercise (P. A. Deuster et al., 2002; Warber et al., 
2000) as well as its effect on muscular strength (Bellar et al., 2015). With the known 
important role of acetyl-choline (ACh) for muscular contraction, supplementation with 
various types of choline are intriguing.  
One specific type of choline supplementation that has been proven to be a very 
effective ACh precursor is Alpha-GPC supplementation (Kawamura et al., 2012). Alpha-
GPC supplementation has limited previous research with regards to muscular performance 
(Bellar et al., 2015; Ziegenfuss, 2008). One current limitation concerning Alpha-GPC 
supplementation is that is has only been investigated as a single ingredient supplement. 
Myosync™ not only includes Alpha-GPC as its main ingredient, but also several other 
ingredients to promote the effects of increased ACh.  
Due to the importance of lower extremity strength and rate of force development 
(RFD) in everyday life as well as athletics, various research methods have been used to 
assess these measures (Aagaard, Simonsen, Andersen, Magnusson, & Dyhre-Poulsen, 
2002; Andersen & Aagaard, 2006; Young et al., 2005). The method of testing used to assess 
strength and RFD can depend on many variables such as subject population as well as 
equipment available to researchers. A common method that has been used previously in 
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research the utilization of a dynamometer such as a Biodex. Using this method, researchers 
can assess various aspects of strength (isometric, dynamic, eccentric) while also getting 
sufficient data relating to RFD. Previous researchers have used various time points at the 
start of the isometric MVC (0-10, 0-20, 0-30, 0-250 ms) and assessed the slope of the 
torque-time curve to determine RFD.  (Aagaard et al., 2002). This is a good way to isolate 
the knee extensor muscle group and gather information regarding an individual’s MVC.  
 Purpose and Hypothesis 
Athletic performance is very important to many individuals from the high-school level all 
the way to the professional levels. One main interest for many athletes is the topic of 
supplementation as stated by Lavallee (2012) but unfortunately the research to support 
effects of various supplements is lacking. Gaining an understanding of the benefits that 
supplements provide, along with proper usage of these supplements can lead to a great 
understanding in regard to improving physical performance. Furthermore, many 
supplements contain multiple ingredients and stimulants that are designed to enhance some 
aspect of physical performance. With the mixed results concerning the effect of Alpha-
GPC to increase strength or power (Bellar et al., 2015; Ziegenfuss, 2008) the additional 
ingredients contained in Myosync™ could lead to significant results.  The purpose of this 
study is to examine the effects of a supplement, Myosync™ on physical performance in 
Division II collegiate football players using both practical and laboratory based testing 
measures. To the author’s knowledge, this is the first study to investigate the effects of 
Myosync™ on physical performance. Based off previous literature conducted by Bellar et 
al. (2015), it was hypothesized that subjects would show an increase in physical 
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performance as measured by vertical jump height, maximal isometric strength as well as 
maximal dynamic strength and power with supplementation of Myosync™.  
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2. Literature Review 
 Supplementation and Physical Performance  
One aspect of performance that athletes are continuously trying to improve is maximal 
strength and rate of force development due to its importance in a variety of athletic 
movements (Andersen & Aagaard, 2006). Throughout the recent history of studying 
athletic performance; supplementation has been an area of interest for researchers. 
Supplements are used to improve energy metabolism through either increasing energy 
sources available or improving metabolic processes that generate those energy sources 
(Kanter & Williams, 1995). Various types of pre-workout supplements have been available 
for athletes to use but further research is necessary to assess the efficacy of these 
supplements.  
 Muscular Strength and Rate of Force Development  
Muscular strength has previously been defined as the muscles ability to exert force on an 
external object or resistance (Suchomel, Nimphius, & Stone, 2016) . Similarly, Aagaard et 
al. have defined Rate of Force Development (RFD) as the rise in force over a change in 
time (Aagaard et al., 2002). With today’s high level of competition in athletics, athletes are 
required in many sports to exert a very high amount of force over a very short period of 
time. Because athletes are required to produce maximal amounts of force within 50-250 
ms (Andersen & Aagaard, 2006), RFD has become a very important aspect of training for 
many athletes. Some various examples of skills in athletics that demonstrate an athletes 
need for a high RFD are, sprinting, jumping, and change of direction (COD).   
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Limited research exists related to the supplementation of Alpha-GPC and isometric 
strength (Bellar et al., 2015) which concluded that an acute dose of Alpha-GPC did not 
significantly improve isometric strength. However, after six days of 600 mg Alpha-GPC, 
significant increases in lower body isometric strength were observed. Furthermore, an 
additional study testing the effects of choline ingestion on various aspects of physical 
performance and saw no improvements in hand grip strength or lower body strength 
(Patricia A. Deuster, 2002). One possible limitation with the previously mentioned studies 
could be the testing protocol used to assess lower body strength. Although the testing 
protocol utilized by Bellar et al. (2015) included an isometric mid-thigh pull, which is a 
common weight training exercise, the amount of technique that is required to properly 
execute the exercise and produce maximal results could require experience that not all 
subjects may have had. The measurement for strength in the study conducted by P. A. 
Deuster et al. (2002) was a load carry test. Although this type of test can give great insight 
into other muscular factors such as muscular endurance, it is difficult to quantify maximal 
strength with this particular test. With the importance of isometric strength and RFD seen 
throughout athletics, testing protocols for these qualities need to be improved and 
standardized to ensure consistent measurements.       
 Common Pre-workout Supplements  
Caffeine is one of the most commonly used supplements due to its effectiveness at 
stimulating the central nervous system resulting in increased alertness and focus (Astorino 
& Roberson, 2010). Through a study conducted in 2008 to assess the effect of caffeine 
ingestion (5 mg/kg body mass) on repeat sprint ability, it was found that caffeine has 
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ergogenic properties that improve not only single sprint time but also times in multiple 
sprints (Glaister et al., 2008). A study looking into the effects of supplementing with 400 
mg of caffeine (approximately 4.9 mg/kg/body weight) in 21 untrained males showed no 
effect on either upper or lower body strength as well as no effect on endurance cycling 
performance (Hendrix et al., 2010).  
In addition to caffeine supplementation, another common pre workout supplement is 
beta-alanine. In a study looking at the effect of beta-alanine supplementation in trained 
sprinters, it determined that oral supplementation was able to significantly increase the 
muscle carnosine levels as well as attenuate fatigue (Derave et al., 2007). A summary of 
previous supplementation studies is presented below in Table 1.  
Due to the large amount of pre-workout supplements available on the market today, 
it is important that both positive and negative effects of supplements are well-known to not 
only the researchers but the consumers as well. 
Table 1. Review of Literature  
Study Subjects Supplement Measurements Outcome 
Bellar et al. 
(2015) 
13 college 
aged 
males. 
 Alpha-GPC 
(600 mg/day) 
Upper and 
lower body 
isometric 
strength 
No acute effects of 
Alpha GPC 
supplementation. Six 
days of 
supplementation 
increased lower 
body force 
production.  
Claudino et al. 
(2014) 
14 
Brazilian 
elite 
soccer 
players 
Creatine (20 
g/day 1 week; 
5 g/day 6 
weeks) 
Lower body 
power (counter 
movement 
jump) 
Creatine 
supplementation 
prevented loss in 
lower limb muscle 
power throughout 
pre-season training. 
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Derave et al. 
(2007) 
15 male 
athletes 
Beta-alanine 
(4.8 g/day for 
4 weeks) 
5 sets of 30 
maximal knee 
extensions; 
400- m sprint 
time 
Supplementation 
improved torque 
during 4th and 5th 
sets of knee 
extension. No effect 
on 400-m sprint 
time. 
Patricia A. 
Deuster (2002) 
13 males  Choline 
(50mg/kg 
body weight) 
Upper and 
lower body 
strength and 
endurance 
measures  
Supplementation did 
not have any effect 
on physical 
performance.  
Glaister et al. 
(2008) 
21 
physically 
active 
males  
Caffeine (5 
mg/kg body 
weight) 
Repeat Sprints 
(12 x 30 m at 
35 second 
intervals) 
Resulted in 1.4% 
decrease in fastest 
sprint time; 1.2% 
increase in fatigue 
Hendrix et al. 
(2010) 
21 
untrained 
males 
Supplement 
containing 
400 mg 
caffeine  
1 RM bench 
press and leg 
extension; Time 
to exhaustion at 
80% VO2 peak 
cycling.  
Results showed no 
effect on 1 RM 
bench press, leg 
extension or time to 
exhaustion.  
Kawamura et 
al. (2012) 
8 healthy 
males  
Alpha-GPC 
(1000 mg)  
Plasma choline 
levels; Plasma 
growth 
hormone levels.   
Increase in plasma 
free choline levels at 
60 minutes with 
supplementation. 
Increase in plasma 
growth hormone 
secretion. 
Scholey et al. 
(2010) 
32 healthy 
young 
adults 
Cereboost 
(100, 200, 
400 mg trials) 
Mood, 
cognitive 
function, and 
blood glucose 
(1, 3 and 6 hrs 
following 
supplement-
ation) 
Supplementation 
showed significant 
improvement in 
working memory 
across all doses and 
time points. 
Warber et al. 
(2000) 
14 Choline 
Citrate (8.425 
g) 
4 hour load 
carriage 
treadmill test 
(Load 34.1 kg) 
Choline levels 
increased 128% with 
supplementation, but 
did not deplete 
during placebo. No 
performance 
changes during test. 
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Ziegenfuss 
(2008) 
7 males  Alpha-GPC 
(600 mg) 
6 sets of 10 reps 
of Smith 
machine squats 
at 70% 1RM; 3 
sets of bench 
press throws at 
50% 1RM 
Supplementation 
increased peak 
bench press force; 
No effect on peak 
power or rate of 
force development. 
 
 
 Choline Supplementation  
Choline was first officially recognized by the Institute of Medicine as an essential nutrient 
in 1998 (Zeisel & da Costa, 2009), and  can be found naturally in eggs, red meat, milk, and 
fish (Cho et al., 2006). Choline supplementation is a well-known method used as an Acetyl 
Choline (ACh) precursor that has been researched in both the medical and physical 
performance disciplines (Conlay, Sabounjian, & Wurtman, 1992; Costa, 2009; Lavallee, 
2012). Supplementation with ACh precursors has focused on both physical/physiological 
effects as well as effects on cognitive function in individuals. Specifically, Alpha-GPC has 
been shown to be a highly effective precursor for ACh (Kawamura et al., 2012).  With the 
majority of the research surrounding choline supplementation pertaining to 
neurodegenerative disorders such as Alzheimer’s disease (da Rocha et al., 2011; Zeisel & 
da Costa, 2009) there are still many questions about its ability to increase physical 
performance.  
The majority of previous research assessing the effect of Alpha-GPC or other 
various forms of choline supplementation have focused on endurance athlete performance 
(Conlay et al., 1992; Warber et al., 2000). Previously, research has investigated the effect 
of prolonged exercise on plasma choline levels. One of the findings from previous research 
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states that after completing the Boston Marathon, runners showed a 40% reduction in 
plasma choline levels (Conlay, Sabounjian et al. 1992). With depeleted levels of plasma 
choline, one could infer that acteylcholine release could be inhibited or decreased at the 
neuromuscular junction level. Because the previously mentioned study did not investigate 
the effect of choline supplementation on levels of plasma choline, it is difficult to come to 
any conclusions other than prolonged aerobic exercise has been shown to deplete levels of 
plasma choline.  Other previous studies have investigated the effect of elevating plasma 
choline levels above their basal levels with aims at investigating if the elevated plasma 
choline levels had any effect on performance in endurance exercises (Patricia A. Deuster, 
2002; Warber et al., 2000).  
The study conducted by Warber et al. (2000) examined physical performance in a 
battery of tests including a four hour load carriage test on a treadmill, run time-to-
exhaustion test, along with squat testing. This study found that with supplementation of 
choline citrate (8 grams) it was possible to increase plasma choline levels by 128%, but 
failed to find any change in levels of plasma choline when subjects ingested the placebo 
beverage. It is important to note that there were no observed increases in physical 
performance with choline supplementation and elevated levels of plasma choline. Based 
on the results indicating no depletion of plasma choline during the placebo trial, it is 
reasonable to conclude that the exercise protocol may not have been sufficient enough to 
show similar decreases in plasma choline as previously shown by (Conlay et al., 1992). 
Similar to the previously mentioned study, Patricia A. Deuster (2002) investigated the 
effect of choline supplementation during a timed load carriage test. It was concluded that 
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choline supplementation was successful in elevating plasma choline levels; however, it did 
not show any improvements in the time to fatigue during the load carriage test.   
 It has been known that weakened impulse transmission along with impaired skeletal 
muscle performance have been associated with reduced concentrations of free choline 
during exercise (Conlay et al., 1992). When plasma choline levels have been shown to 
decrease during intense physical activities, short term choline supplementation (10 days) 
has shown improvements in exercise capacity during high intensity cycling and intermittent 
running (Jäger, Purpura, & Kingsley, 2007).  
 As it has been shown, choline supplementation has been studied for many years 
concerning performance in various activities involving prolonged exercise. One area that 
is just beginning to gain interest is choline supplementation with regards to maximum 
strength and explosive exercise. Due to the known importance of ACh for muscular 
performance, further research is necessary to investigate these effects.  
 
 Myosync ™ 
Previous research has been focused on the supplementation of the individual ingredient 
Alpha-GPC (Bellar et al., 2015; Ziegenfuss, 2008) or other various forms of 
supplementation (Buchman, Jenden, & Roch, 1999; Penry & Manore, 2008). The current 
product Myosync ™ not only includes Alpha-Size Alpha-GPC, to serve as an acetylcholine 
precursor, it also includes other ingredients that are aimed to promote and enhance the 
effect of the main ingredient, Alpha-GPC. Ingredients included in the Neuromuscular 
response Matrix include: Alphasize® 50% Alpha-Glyceryl Phosphoryl Choline, Panax 
23  
quinquefolius extract, Vinpocetine, Huperzia serrata, Rosmarinus officinalis extract and 
Bioperine® black pepper extract.   
Alpha-GPC: Alpha-GPC is a putative acetyl choline precursor that has the potential 
to increase growth hormone (GH) secretion via acetyl-choline stimulated catecholamine 
(Kawamura et al., 2012). As previously stated, Alpha-GPC has been studied previously 
alone as a single ingredient supplement. One previous study conducted by Bellar et al. 
(2015) was the first study to investigate the effect of Alpha-GPC supplementation on 
isometric strength. Bellar et al. (2015) found no acute effect with regards to an increase in 
isometric strength, however they did find after 6 days of supplementation isometric 
strength was increased. It was also observed in a separate study that a single dose of 1000 
mg of Alpha-GPC was shown to increase the plasma GH levels significantly after 60 
minutes of ingestion when compared to a placebo (Kawamura et al., 2012).  
Panax Quinquefolius Extract: Also known as American Ginseng has been studied 
recently and has shown promising effects on improving aspects of human cognitive 
function. A 2010 study looked into the effects of 3 different doses of the supplement 
Cereboost™ which contained panax quinquefolius extract standardized to 10.65% 
ginsenosides. This study found great improvements in working memory as well as reaction 
time through the different doses associated with panax quinquefolius (Scholey et al., 2010). 
Furthermore, an additional study looking into the effectiveness of panax quinquefolius 
extract in treating Alzheimer disease found that after a 12 week period of daily 
supplementation of 4.5g/d, patients began to show improvements in various cognitive 
function assessments (Lee, Chu, Sim, Heo, & Kim, 2008). 
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Huperzia Serrata: Huperzine A is an alkaloid that can be isolated from the Chinese 
herb Huperzia serrata, is a very effective and highly specific inhibitor of 
acetylocholinesterase (AChE) (Wang, Yan, & Tang, 2006). AChE is an enzyme that is 
responsible for the removal of ACh, by inhibiting this enzyme, the neurotransmitter ACh 
will remain longer in the neuromuscular junction. When studied in rats, compared with the 
other AChE inhibitors Donepezil, Tacrine, Rivastigmine and Physostigmine, Huperzine A 
was shown to have a much greater effect on AChE (Zhao & Tang, 2002).  
Vinpocetine: A large amount of the previous research involving vinpocetine has 
pertained to cerebrovascular disease as well as cognitive disorders such as dementia and 
Alzheimer’s (Patyar, Prakash, Modi, & Medhi, 2011; Szapáry et al., 2012). It was shown 
in the study conducted by Balestreri, Fontana, and Astengo (1987) that vinpocetine 
supplementation three times daily was able to improve scores on a variety of cognitive 
assessments.  
Rosmarinus officinalis extract: Rsomarinus officinalis extract has been shown to 
have the potential to serve as an agent to aide in the prevention of various human 
neurodegenerative disorders caused by oxidative stress (Park, Kim, Sapkota, & Kim, 
2010). 
Bioperine® black pepper extract: Bioperine black pepper extract has been one of 
various ingredients contained in thermogenic dietary supplements (Outlaw et al., 2013). 
Previously it has been found that supplementation of coenzyme Q10 with an additional 5 
mg of Bioperine® increased plasma levels of coenzyme Q10 more so than supplementation 
with coenzyme Q10 alone (Badmaev, Majeed, & Prakash, 2000). The increase in plasma 
levels of coenzyme Q10 observed in the study conducted by Badmaev et al. (2000) could 
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indicate that Bioperine® supplementation may increase the bioavailability of other 
nutrients.    
With the addition of the various previously studied ingredients just discussed, 
Myosync™ could provide better improvements in physical performance than seen 
previously with Alpha-GPC supplementation.   
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3. MATERIALS AND METHODS 
 Subjects  
Following a reading of the testing procedures along with the benefits and risks associated 
with the study, written consent was obtained by each individual before their participation 
began.  This study was approved by the Michigan Technological University’s Institutional 
Review Board for the protection of human subjects. 
Fourteen Division II college football players volunteered to participate in the study. 
Subjects were free from musculoskeletal disorders that would impair their ability to 
exercise. Subject characteristics are summarized in Table 2. 
All subjects attended a familiarization session that involved completing a physical 
activity questionnaire (Kriska & Bennett, 1992), handedness questionnaire (Oldfield, 
1971), collection of subject characteristics and vitals, habituation of the electrical-
stimulation to the vastus lateralis, vastus medialis, rectus femoris muscles and practice of 
maximal voluntary isometric contractions (MVIC). The experiment was designed as a 
double blind randomized crossover experiment with subjects participating in two 
experimental sessions (placebo control and supplemental), each separated by seven days. 
Subjects were asked to refrain from strenuous exercise for 24 hours prior to each of the two 
experimental sessions to insure the quality of performance during each testing session. 
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Table 2. Subject characteristics 
Variables Value (n = 14) 
Age (years) 20.4 ± 1.0 
Height (cm) 191.4 ± 5.5 
Weight (kg) 106.9 ± 16.4 
Body fat (%) 17.7 ± 5.4 
Physical activity (MET h/wk) 139.2 ± 55.9 
Handedness (a.u) 40.7 ± 65.4 
BMI (kg/m2) 29.1 ± 3.8 
 Experimental Set-up 
Experimental sessions included a variety of physical and muscle function testing. The 
testing consisted of several baseline measures including maximal vertical jumps, MVICs , 
and maximal voluntary concentric contractions. Fatiguing contractions were then 
completed followed by reassessment of baseline measures 10 minutes post completion of 
fatiguing task. All muscle function testing began one hour after subject ingested either two 
capsules of a control (Fiber) or two capsules of Myosync™ (1,076 mg/capsule).  
3.2.1. Vertical Jump 
 A Vertec vertical jump tester (Vertec, JumpUSA, Sunnyvale, Ca. USA) was used to 
measure vertical jump height. The Vertec device was placed directly over the subject as 
seen in Figure 1 and the subject was instructed to hit the Vertec at the peak of their jump 
height.   
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Figure 1. Subject walks under the Vertec with both arms extended overhead to 
asses standing reach (left). Subject prepares for maximal countermovement jump 
(right). 
3.2.2. Dynamometer 
A Biodex multi-joint dynamometer (System 4 Pro; Biodex Medical System, Shirley, NY, 
USA) was used for testing. This particular  dynamometer has been shown to perform with 
acceptable trial-to-trial and day-to-day mechanical reliability and validity for testing  angle, 
torque and velocity measures using various muscle groups (Drouin, Valovich-mcLeod, 
Shultz, Gansneder, & Perrin, 2004). Each participant was seated in a slightly reclined 
position with the hip and knee angle at 95° and 90°, respectively.  Participant’s shank was 
strapped to the distal end of the Biodex arm, with the lateral epicondyle of the femur 
aligned with the axis of rotation of the dynamometer. 
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All voluntary isometric contractions were performed at 90 degrees of flexion (0 
degrees being horizontal).  The angle of 90 degrees was chosen based on results from pilot 
testing and previous  literature De Ruiter, Kooistra, Paalman, and de Haan (2004) 
indicating it to be an effective position for torque development and muscle activation. 
Shortening contractions began at 90 degrees of flexion and moved through to 30 degrees 
of flexion. Therefore, all dynamic contractions moved through a 60 degree range of motion. 
Torque, angle, and angular velocity data were sampled at a rate of 2000 Hz using a micro 
1401 AD converter and Spike 2 software (Version 8, Cambridge Electronics Design, 
Cambridge, UK). Torque signal was displayed on a 70-in TV monitor (Sharp Electronics, 
NJ, USA) located 2.5 m in front of the subject. 
3.2.3. Electromyography Recordings 
Surface electromyography (EMG) system (Bagnoli 16; Delsys, Natick, MA., USA) was 
used to record activity of the knee extensor muscles, including the rectus femoris, vastus 
lateralis and vastus medialis throughout the testing. Electrode placement (see Figure 2) 
was determined according to recommendations by the Surface Electromyography for the 
Non-Invasive Assessment of Muscles (SENIAM Project) (Hermens, Freriks, Disselhorst-
Klug, & Rau, 2000). The ground electrode was positioned over the patella. The skin was 
thoroughly scrubbed with alcohol soaked cleansing cloths before electrode placement, and 
location was marked via a permanent pen to ensure placement was consistent for the 
entirety of the testing sessions. The EMG signal was sampled at a rate of 2000 Hz using a 
micro 1401 AD converter and Spike 2 software (Version 8, Cambridge Electronics Design, 
Cambridge, UK). 
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3.2.4. Electrical Stimulation 
Electrical pulse (singlet, square wave, 100-μs duration) was applied using a computer-
controlled stimulator (D185; Digitimer, Welwyn Garden City, UK) and a pair of self-
adhesive surface electrodes (6.98 x 12.7 cm, Dura-Stick plus DJO Brands).  The exact 
electrode positions were marked with a permanent pen, which allowed the investigator to 
replicate positioning of electrode pads for subsequent trials.  The cathode electrode was 
place distally in relation to the anode electrode. The superior aspect of the proximal 
electrode was positioned at the height of the greater femoral trochanter with the midpoint 
of the electrode horizontally aligned with the anterior-superior iliac spine (Pietrosimone, 
Selkow, Ingersoll, Hart, & Saliba, 2011). The distal electrode was positioned so that the 
inferior aspect of the electrode sat approximately 3 cm superior to the patella, with the 
medial border of the electrode aligned with the midline of the patella (Pietrosimone et al., 
2011).  See Figure 2 for electrode placement.  At the start of each testing session, the 
stimulation voltage was increased until the twitch torque response leveled off, and it was 
assumed that at that point, all of the knee extensor muscle fibers were fully activated. To 
ensure full activation of all motor units by supramaximal stimulation, voltage was further 
increased by an additional 20%. This supramaximal voltage intensity (120%) was used for 
all electrically evoked contractions for the remainder of the testing session for each 
individual. 
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Figure 2. Electromyography and Electrical Stimulation Electrode Set-up. EMG 
electrodes (black).  Electrical Stimulation electrodes (blue). The ground electrode 
(beige) is positioned over patella. 
 Experimental Protocol  
 
Figure 3. Experimental protocol for both control and supplemental sessions. 
Subjects ingested either control or supplement (random order) at the 0-minute mark 
of each testing session.  
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3.3.1. Baseline Measures  
Maximum Vertical Jump. The subject was asked to walk under the Vertec with both arms 
fully extended overhead in order to obtain the subject’s standing reach. Subjects were 
instructed to walk back and forth until they were no longer able to reach any of the veins 
on the Vertec. This measurement was then used as the subject’s standing reach. After the 
standing reach was determined, the subject was instructed to stand in the center of the force 
plate with the Vertec positioned directly over their head. They then performed three 
maximum vertical jumps separated by one minute each. With each jump the subject was 
instructed to keep their knees fully extended in the air, while reaching to slap the highest 
vein possible at the peak of their vertical jump.  
Maximal Voluntary Isometric Contractions (MVICs). Three MVICs were performed each 
with a contraction time of 3-5 seconds. 120 seconds were given as a rest period in between 
contractions to ensure adequate recovery. If at least two of the three MVIC values were not 
within 5% of each other, a fourth trial was done.  Visual feedback of the live torque-time 
tracing were given to the subjects on a 70-inch TV monitor, as well as verbal 
encouragement to ensure maximal effort during all MVICs. Subjects were instructed to 
attempt to extend their knee as fast and as hard as possible while electrical stimulation was 
applied to at the peak torque level during MVIC. An additional twitch was triggered upon 
relaxation (approximately 1 s) following the MVIC.  
Maximal Voluntary Concentric Contractions (MVCCs). Seven sets of isotonic contractions 
at various pre-determined resistance loads were performed, including 1 Nm, 10%, 20%, 
30%, 40%, 50%, and 60% of MVIC. These loads were in randomized order, and stayed in 
the same randomized order for the duration of the testing procedures per individual. 
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Subjects were instructed to move the resistance load as “fast and hard” as possible 
throughout the full 60° range of motion. Subjects were provided with verbal 
encouragement and real-time torque feedback displayed on a TV monitor to encourage a 
maximal effort (maximal velocity) (Campenella, Mattacola, & Kimura, 2000). Two 
consecutive repetitions at each resistance were performed to improve the chances that true 
maximal velocity was reached. Thirty seconds of rest were allotted in-between sets. The 
peak velocity reached at each resistance load was used to establish baseline values for 
angular velocity at each of the seven resistance loads, with the peak angular velocity 
(obtained at 1 Nm) considered the maximal shortening velocity. Power was calculated 
across each of the seven resistance loads, with the peak power being the highest product of 
torque and velocity at any given time-point during the contraction. 
3.3.2. Fatiguing Contractions  
Subjects performed four sets of 30 repetitions of a dynamic leg extension at a constant load. 
The load used for these contractions was set to 20% of the subject’s MVIC torque value. 
Similar to the MVCCs, subjects were instructed to extend their leg as fast and as hard as 
possible throughout the entire 60 degree range of motion. After each extension, the Biodex 
returned the subjects’ leg passively to 90 degrees in order to perform the next contraction. 
In between each set of 30 repetitions, subjects performed one MVIC (F1, F2, F3, and F4) 
with electrical stimulation in order to assess the subject’s voluntary activation level.  
3.3.3. Recovery Measures 
MVIC and MVCC measurements were performed at 10 minutes post completion of the 
fatiguing task.  
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 Data Analysis 
Spike 2 software was used offline to determine maximum vertical jump, velocity, torque, 
power and EMG as follows.  
3.4.1. Maximum Vertical Jump 
Prior to each testing session subjects had their standing reach assessed by walking 
underneath a Vertec with both arms fully extended overhead. Subjects were asked to walk 
back and forth underneath the Vertec until they were no longer able to make contact with 
any of the measurement veins. This value was used as the “Standing Reach” value and was 
subtracted from the total height the subject was able to reach during each maximal jump.  
3.4.2. MVIC 
Maximal voluntary isometric contraction (MVIC) torque was quantified as the average 
torque of 0.1 s duration prior the event of electrical stimulation during MVIC. When the 
electrical stimulation was not applied at the peak torque, MVIC torque was quantified as 
the average torque value over a period of 0.1 s that was centered about the peak torque. 
During baseline measurements where 3-4 MVICs were measured, the greatest torque 
amplitude amongst all of the trials was recorded and used for analysis.  
3.4.3. Rate of Torque Development  
Rate of torque development during the MVICs was calculated as the peak tangential torque 
using a moving mean method of the torque-time curve over the first 400 ms from the onset 
of contraction (Aagaard et al., 2002).  
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3.4.4. Impulse  
Impulse during each MVIC was calculated as the total area under the torque-time curve at 
specified time points. Impulse was assessed at 200 ms during each MVIC.  
3.4.5. Voluntary Activation 
Voluntary activation (VA) was assessed by measuring the torque response in knee extensor 
electrical stimulation.  Both the peak amplitude of the superimposed twitch (SIT) and the 
resting twitch torque (RT) were used in the following formula (Equation 1) to assess 
voluntary activation:   
Equation 1:  
Voluntary Activation (%) = 100 × (1-SIT/RT) (Merton, 1954). 
Additionally, formula was also used to calculate VA as a supplement, because it 
has the additional correction factor (D) to take into account potential differences between 
the true maximal voluntary torque and the torque value directly prior to the electrical 
stimulation (See Equation 2):  
Equation 2: 
VAcorrected (%) = 100 – (D × (SIT/ MVIC )/RT × 100) (Strojnik & Komi, 2000). 
Equation 2 with the correction factor has previously been shown to be beneficial when 
subjects did not receive the electrical stimulation at their peak maximal voluntary torque 
(Strojnik & Komi, 2000). Values were reported using the Equation 2 (Strojnik & Komi, 
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2000) formula for voluntary activation. This was decided because there was a considerable 
difference between the voluntary activation values  for our data using this formula, versus 
Equation 1 (Merton, 1954) 
3.4.6. Power  
Knee extensor power was represented in Watts and was calculated as the product of torque 
(Nm) and angular velocity (rad/s). Peak power was determined for each of the 7 
predetermined loads based off of the subjects highest baseline value for MVIC.  
3.4.7. Surface Electromyography  
The EMG signal was amplified (x100) and bandpass filtered (10-450 Hz) using a micro 
1401 AD converter and Spike 2 software. EMG of the knee extensor muscles was 
determined as the root mean squared (RMS) value over a 0.1 s interval, which was time 
interval equivalent to the MVC torque measurement. All subsequent MVIC RMS values 
were normalized to the level obtained during baseline.   
 Statistical Analysis 
Data were reported as means ± SD within the text and displayed as means ± SE in the 
figures. Normality and homogeneity were tested using Shapiro-Wilk and Levene tests, 
respectively. Baseline variables including MVIC, RTD, impulse, EMG, and vertical jump, 
were analyzed using a paired t-test to compare between control and supplemental sessions. 
Two-way Analysis of Variance (ANOVA) with repeated measures was used to compare 
dependent variables between sessions (control, supplement) and across time points 
(Baseline, F1, F2, F3, F4; F4, recovery; for fatigue and recovery respectively). The 
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variables include MVIC, RTD, impulse, power, and EMG. For each ANOVA the sphericity 
of data was verified with Mauchly’s test and technical corrections were performed 
whenever necessary. Statistical Package for the Social Sciences (SPSS) software (ver. 21, 
IBM, Armonk, New York, USA) was used for all statistical analysis. An alpha value of P 
< 0.05 was used to identify statistical significance.  
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4. RESULTS 
 Maximum Vertical Jump  
Maximum vertical jump showed no significant difference in jump height between control 
and supplemental sessions (70.8 ± 6.6 vs 70.9 ± 6.2 cm, t13 = -0.135, P = 0.895).  
 MVIC 
Maximal voluntary isometric contraction (MVIC) torque at baseline was similar between 
control and supplemental sessions (297.8 ± 48.4 vs. 296.7 ± 70.5 Nm; t13 = 0.088, P = 
0.931). MVIC torque decreased during the fatiguing contractions (fatigue effect; F1.6, 20.3 = 
45.5, P < 0.001, Ƞ2p = 0.778), and the decline was similar throughout the testing protocol 
between both sessions (fatigue × session; F4, 52 = 0.356, P = 0.839, Ƞ2p = 0.027). After 10 
min of recovery, MVIC torque significantly increased (recovery effect; F1, 13 = 47.31, P < 
0.001, Ƞ2p = 0.784), and the relative increase was similar between sessions (recovery × 
session; F1, 13 = 0.064, P = 0.804, Ƞ2p = 0.005). See Figure 4. 
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Figure 4. MVIC measurements for control and supplemental sessions were similar 
at baseline (297.8 ± 48.4 vs. 296.7 ± 70.5 Nm, P = 0.931) and showed similar 
decrease during fatiguing contractions (P = 0.839) and similar recovery at 10 
minutes post completion of fatiguing task (P = 0.784). 
 Rate of Torque Development 
Rate of torque development (RTD) at baseline was similar between control and 
supplemental sessions (2171.2 ± 564.4 vs. 2156.0 ± 566.6 Nm/s; t13 = 0.140, P = 
0.891). RTD decreased during the fatiguing contractions (fatigue effect; F2.0, 26.6 = 
27.0, P < 0.001, Ƞ2p = 0.675), and the decline was similar throughout the testing 
protocol for both sessions (fatigue × session; F4, 52 = 2.23, P = 0.079, Ƞ2p = 0.146). 
Despite the similar decrease in both sessions, RTD was significantly higher in 
supplemental session compared to control session (1772.7 ± 82.6 vs 1584.9 ± 79.3 
Nm/s; session effect; F 1.0, 13.0 = 7.40, P = 0.018, Ƞ2p = 0.363). After 10 min of recovery, 
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RTD significantly increased (recovery effect; F1, 13 = 54.37, P < 0.001, Ƞ2p = 0.807), 
and the relative increase was similar between sessions (recovery × session; F1, 13 = 
1.96, P = 0.216, Ƞ2p = 0.115). See figure 5.  
 
 
Figure 5. RTD was similar at baseline (P = 0.891) and decreased during the fatiguing 
contractions similarly in both sessions. Despite the similar decrease through 
fatiguing contractions, RTD was greater during the supplemental session throughout 
the fatiguing task (session effect; F = 7.40, P = 0.018).  
 Voluntary Activation  
Voluntary activation was similar between control and supplemental sessions during 
baseline measurements (99.24 ± 1.10 vs. 98.85 ± 1.72 %; t13 = 1.15, P = 0.270). Throughout 
the fatiguing contractions, voluntary activation remained similar between both control and 
supplemental sessions, (session effect; F1, 13 = 2.01, P = 0.180, Ƞ2p = .134). After 10 
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minutes of recovery, voluntary activation was similar between sessions, (recovery x 
session; F1, 13 = 0.163, P = 0.693, Ƞ2p = 0.012).  
 Resting Twitch 
Resting twitch torque was similar between control and supplemental sessions during 
baseline measurements (75.03 ± 13.55 vs. 75.59 ± 15.36 Nm; t13 = -0.162, P = 0.874). 
Throughout the fatiguing contractions, resting twitch decreased (fatigue effect; F4, 52 = 
164.07, P < 0.001, Ƞ2p = .927) and the decrease was similar between both control and 
supplemental sessions, (fatigue x session; F4, 52 = 0.838, P = 0.507, Ƞ2p = 0.061). After 10 
minutes of recovery, resting twitch increased significantly (recovery effect; F1, 13 = 87.62, 
P < 0.001, Ƞ2p = .871) and the increase was similar between sessions (recovery x session; 
F1, 13 = .932, P = .352, Ƞ2p = 0.067). 
 Impulse  
Impulse during the first 200 ms of MVIC at baseline were similar between control and 
supplemental sessions (27.18 ± 6.55 vs. 28.51 ± 7.10 N/s; t13 = -1.14, P = 0.276). Impulse 
decreased throughout the fatiguing contractions, (fatigue effect; F 1.92, 24.90 = 38.7, P < 
0.001, Ƞ2p = 0.749), and the decline was similar throughout the testing protocol for both 
sessions (fatigue x session; F4, 52 = 0.623, P = 0.648, Ƞ2p = 0.046). Despite the similar 
decrease for impulse throughout the fatiguing protocol, impulse was greater for subjects 
during the supplemental session when compared to the control session throughout the 
fatiguing contractions (20.30 ± 0.87 vs. 18.33 ± 0.93 Nms; session effect; F1.0, 13.0 = 28.94, 
P < 0.001, Ƞ2p = 0.690). After 10 min of recovery, impulse increased significantly 
(recovery effect; F1,13 = 48.06, P < 0.001, Ƞ2p = 0.787), and the relative increase was similar 
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between sessions (recovery x session; F1,13 = 0.240, P = 0.633, Ƞ2p  = 0.018). See Figure 
6. 
 
Figure 6. Impulse was similar at baseline and decreased similarly throughout the 
fatiguing contractions. Despite the similar decrease through fatiguing contractions, 
impulse at 200 ms was greater during the supplemental session (session effect; F = 
28.94, P < 0.001). 
 Power 
Knee extensor power showed no significant differences across all loads between control 
and supplemental sessions (F1,13= 3.77, P = 0.074, Ƞ2p  = 0.225). Knee extensor power 
decreased significantly from baseline to after fatigue (time effect; F1,13= 19.87, P = 0.001, 
Ƞ2p  = 0.604) and the decrease between sessions were similar (session x time; F1,13 = 0.099, 
P = 0.758, Ƞ2p = 0.008). The decrease across all loads was similar from baseline to recovery 
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for all load conditions (session × intensity × time; F6, 78 = 0.551, P = 0.767, Ƞ2p  = 0.041). 
See Figure 7.  
 
Figure 7. Peak power decreased after fatiguing contractions for all load conditions 
similarly between control and supplemental sessions.  
 
 Torque and Power during Fatiguing Contractions 
Average torque through the fatiguing contractions decreased similarly between control and 
supplemental sessions (F1, 13 = 0.002, P = 0.961, Ƞ2p < 0.001). Average torque decreased 
throughout the sets of fatiguing contractions (time effect; F7, 91 = 93.8, P < 0.001, Ƞ2p = 
0.878) and the decrease was similar between control and supplemental sessions (session × 
time; F7, 91 = 0.878, P = 0.527, Ƞ2p = 0.063). See Figure 8.  
Average power through the fatiguing contractions decreased similarly between 
control and supplemental sessions (F1, 13 = 1.37, P = 0.263, Ƞ2p  = 0.095). Average power 
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decreased throughout the sets of fatiguing contractions (time effect; F7, 91 = 170.0, P < 
0.001, Ƞ2p  = 0.929) and the decrease was similar between control and supplemental 
sessions (session × time; F7, 91 =1.45, P = 0.194, Ƞ2p = 0.101). See Figure 9. 
Figure 8. Average torque from first and last 5 repetitions of each set during the 
fatiguing contractions. Average torque decreased similarly throughout the fatiguing 
contractions for both control and supplemental sessions.  
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Figure 9.  Average power from first and last 5 repetitions of each set during the 
fatiguing contractions. Average power decreased similarly throughout the fatiguing 
contractions for both control and supplemental sessions.  
 
 Surface Electromyography  
Electromyography activity was examined during the MVIC contractions for the following 
knee extensor muscles: rectus femoris, vastus medialis, and vastus lateralis. EMG 
decreased from baseline through the fatiguing contractions similarly between control and 
supplemental sessions, for rectus femoris (session effect, F1,13 = 0.981, P = 0.340, Ƞ2p = 
0.070) (See Figure 10), vastus medialis (session effect, F1,13 = 0.023, P = 0.881, Ƞ2p = 
0.002) (See Figure 11), and for vastus lateralis (session effect, F1,13 = 0.377, P = 0.550, 
Ƞ2p = 0.028) (See Figure 12). EMG activity showed similar recovery between sessions, 
for rectus femoris (session effect, F1,13 = 4.46, P = 0.055, Ƞ2p = 0.255), vastus medialis 
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(session effect, F1,13 = 0.371, P = 0.553, Ƞ2p = 0.028), and for vastus lateralis (session 
effect, F1,13 = 0.719, P = 0.412, Ƞ2p = 0.052).  
 
 
Figure 10.  Rectus femoris EMG measured during each MVIC shows similar 
decreases between control and supplemental sessions. 
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Figure 11.  Vastus medialis EMG measured during each MVIC shows similar 
decrease between control and supplemental sessions. 
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Figure 12. Vastus lateralis EMG activity measured during each MVIC shows 
similar decreases between control and supplemental sessions. 
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5. DISCUSSION 
 Key Findings  
The current study tested the acute effect of supplementing Myosync™ on physical 
performance in Division II football players. The study compared physical and muscle 
function testing results between a supplemental and control session in a double blind cross-
over procedure.  Contrary to the hypothesis, supplementation with Myosync™ did not 
show improvements in vertical jump height or maximum isometric strength.  
The new findings from the current study are, 1) Acute supplementation with 
Myosync™ does not have an effect on vertical jump height;  2) Acute supplementation 
with Myosync™ showed no significant improvements in MVIC strength or dynamic 
power;  3) Acute supplementation with Myosync™ did show significant improvements in 
rate of torque development and impulse; 4) Acute supplementation with Myosync™ 
showed no effect on fatigue.  Given that maximal strength has previously been significantly 
correlated with voluntary RFD (Mirkov, Nedeljkovic, Milanovic, & Jaric, 2004) increases 
in the current study for RFD and not maximal strength are intriguing. The results of the 
current study suggest that it is possible to improve RFD without improvements in maximal 
strength, which could be an area of interest for many athletes and coaches.  
 Vertical Jump  
To the author’s knowledge, this is the first study to investigate the effect of Myosync™ 
supplementation on practical measures of athletic performance such as the vertical jump 
height. The results of the current study indicated no change in vertical jump height which 
agree with previous research involving supplementation and vertical jump height (Bunn, 
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Crossley, & Timiney, 2017; Claudino et al., 2014). Previously, Bunn et al. (2017) 
concluded that 500 mg Alpha-GPC supplementation showed no improvements in vertical 
jump height when tested against a placebo. Claudino et al. (2014) found that creatine 
supplementation for professional soccer players failed to reach statistical significance when 
comparing vertical jump performance against a placebo. It has been shown that ten weeks 
of barbell deadlift training increased RFD along with vertical jump in novice weight lifters 
(Thompson et al., 2015). The increases in both RFD and vertical jump that were seen in 
the novice subjects were likely due to the early training adaptations that occurred over the 
ten-week period of training. It has previously been shown that individuals who are 
untrained will make better adaptations to training then previously trained individuals 
during a 21-week supervised training regimen (Ahtiainen, Pakarinen, Alen, Kraemer, & 
Häkkinen, 2003). Many times there is a disconnect between researchers and sport coaches 
or players, and that disconnect can lead to a lack of respect for research from athletes or 
coaches. Future research pertaining to athletic performance should attempt to include both 
practical assessments such as vertical jump and sprint time, along with laboratory 
measurements to support those practical measures.   
 Isometric Strength and Rate of Torque Development 
Maximal strength is a very important aspect of athletics across a wide variety of sports. 
Depending on the nature of the sport, athletes typically have to generate large amounts of 
strength in very short amounts of times. Previously, it has been found that increases in 
maximal strength lead to improvements in RFD (Aagaard et al., 2002). Currently, to the 
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authors’ knowledge, no other studies have yet to compare the effect of Myosync™ on 
muscle strength and performance.  
Based on the results of the current study, it was found that supplementation with 
two capsules of Mysoync™ did not show significant improvements in maximal isometric 
strength. A similar study conducted by Bellar et al. (2015) found no difference in isometric 
lower body strength when looking at the effects of acute supplementation with Alpha-GPC 
supplementation; however they found a significant increase in lower body isometric 
strength after a six day loading phase of Alpha-GPC supplementation. One possible 
explanation for not finding increases in isometric strength during the current study could 
be because the subjects were not given enough dosage of Myosync™. The recommended 
dosage by the manufacturer states athletes may need anywhere between two and four 
capsules for supplementation based on the level and training year of the athletes. Another 
possible explanation for the lack of improvement in isometric strength that would agree 
with the findings of Bellar et al. (2015) is that the current study involved no loading phase 
of the supplement.  
Furthermore, maximal strength has recently been a topic of discussion when 
training athletes. It is well known that increases in strength have been shown lead to 
improvements in sport performance, resulting in better performance while sprinting, 
jumping, and change of direction (Suchomel et al., 2016). More recently, the question has 
shifted towards, how much strength is necessary, and when should the athletes training 
emphasis shift towards speed and power production. This question has led many 
researchers to investigate the association between strength improvements and changes in 
sport performance. 
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It has been previously stated that given the unpredictable nature of athletics, athletes 
have to generate as much force as possible between 50-250 ms which is not enough time 
to generate maximal strength (Andersen & Aagaard, 2006). Because of this, many 
researchers and coaches have placed equal if not more importance on the RFD. The results 
of the current study indicate that RFD during MVICs showed significant improvement 
during the supplemental session. Results from previous research conducted by Andersen 
and Aagaard (2006) showed that at time intervals later than 90ms from the onset of 
contraction, maximal strength could account for 52-81% of the variance in voluntary RFD. 
Contrary to the results of Andersen and Aagaard (2006) the current study measured RFD 
at a time of 400 ms from the onset of contraction showing no increase in maximal strength 
but an increase in RFD. A previous review of the literature  has investigated various 
mechanisms that influence RFD including neural and peripheral mechanisms (Maffiuletti 
et al., 2016). One of the major influences on RFD especially early in a voluntary contraction 
is motor unit recruitment and discharge rate. It has been shown by Desmedt and Godaux 
(1977) that contrary to slow contractions, which have a progressively increasing motor unit 
discharge rate, faster contractions generally have a high initial discharge rate that decreases 
over the length of the contraction. With the results showing no significant difference in 
voluntary activation, but a reduction in resting twitch torque, it can be concluded that the 
peripheral mechanism of fatigue contributed significantly to MVIC and consequently RFD. 
Muscle size is another mechanism that has been shown to improve RFD, showing increases 
in muscle size and cross sectional area have led to improved RFD (Andersen & Aagaard, 
2006). The increases seen in RFD through the current study could be a result of the motor 
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unit discharge rate not decreasing as rapidly during the voluntary contractions with 
supplementation of Myosync™. 
 The current study was not able to measure the amount of acetylcholine present in 
the neuromuscular junction but it seems logical to assume that an increased amount of 
acetylcholine present would allow for better recruitment of motor units within a shorter 
amount of time. Because an increase in maximum strength would involve activating more 
muscle fibers, the idea of being able to activate the muscle fibers available faster would 
seem more logical when discussing supplementation for athletes.  These findings suggest 
that it is possible to increase the RFD with supplementation. Based on the results of 
increased RFD, athletes could potentially improve performance in their sport by 
supplementing with Myosync™.  
 Power Measurements  
With power being defined as the product of torque and velocity, investigation of 
performance during dynamic contractions can have strong implications for various sports. 
Similar to isometric strength, limited research has been conducted investigating the effect 
of Alpha-GPC supplementation on dynamic power. Furthermore, to the authors’ 
knowledge, no research has examined the effects of supplementation with Myosync™ on 
dynamic power.  
The current study measured power using dynamic contractions with various loads 
based of the individuals MVIC value (1nm, 10, 20, 30, 40, 50, and 60%). With results 
showing no difference in the baseline or recovery power values between sessions, it can be 
concluded that supplementation with Myosync™ provided no benefit in increasing power 
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throughout the dynamic contractions. Because there were no differences overall with 
regards to isometric strength, subjects were moving similar resistances during both 
sessions. With the load being relatively consistent between sessions, one can conclude that 
in order to show increases in power, subjects would have had to increase the velocity of 
the contraction.  
The current study was unable to detect in power production through a dynamic 
contraction with supplementation, it is important to note that the majority of research 
pertaining to Alpha-GPC supplementation has been conducted using isometric muscle 
testing. One pilot study conducted by Ziegenfuss (2008) showed a 14% increase in peak 
bench press force by supplementing with an Alpha-GPC supplement. More research is 
necessary to investigate the role of Alpha-GPC supplementation during dynamic 
contractions to investigate the effects on dynamic strength and power.  
 Fatigability 
Fatigue is a reduction in muscle force or power production. The protocol used in the current 
study to induce muscle fatigue was chosen in an attempt to mimic the demands of athletics. 
For the purpose of the current study, muscle fatigue was analyzed in multiple ways such 
as reduction in MVIC, reduction in resting twitch torque production, reduction in voluntary 
activation, as well as monitoring torque and power production throughout the 120 fatiguing 
contractions.  
Previous research has assessed the effect of choline supplementation on 
performance during prolonged exercise such as load carriage tasks and cycling (Spector et 
al., 1995; Warber et al., 2000). Similar to the results found in the current study, Spector et 
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al. (1995) found that choline supplementation did not improve performance in 
supramaximal brief or prolonged submaximal cycling, It is important to note that the 
previously mentioned study did not notice significant levels of choline depletion during 
either testing condition (Spector et al., 1995). Similarly, Warber et al. (2000) showed no 
improvements in prolonged exercise performance with choline supplementation.  
Due to the fact that reductions in MVIC were seen immediately after the first set of 
30 fatiguing contractions and those reductions were similar between both sessions, it is fair 
to conclude that supplementation did not have an impact on preserving isometric strength 
throughout the testing protocol. It is still important to acknowledge that although MVIC 
strength  decreased similarly between sessions, rate of torque development did not decrease 
as much during the MVIC throughout the fatiguing protocol for the supplemental session.  
The decrease in torque and power through each set of fatiguing contractions was 
also used to quantify the amount of muscle fatigue. By analyzing the first and last five 
contractions of each set of 30 of fatiguing contractions, it was shown that the rate of fatigue 
was similar between both sessions. The smallest decrease in both torque and power 
occurred during the first set of fatiguing contractions, with larger and more significant 
decreases occurring during sets two, three, and four.  
To the author’s knowledge, this is the first study to assess neuromuscular fatigue 
while assessing the effect of an Alpha-GPC supplement on muscular strength and 
fatigability. With electrical stimulation, the authors assessed resting twitch torque and 
voluntary activation which are variables others researching this area were not able to use. 
Using the corrected voluntary activation equation described previously, there was no 
change observed in voluntary activation throughout any of the MVICs across both sessions. 
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This shows that although isometric strength was decreased and fatigue was observed, the 
fatigue was not likely due to central fatigue. Unlike voluntary activation, the resting twitch 
elicited by electrical stimulation did show decreases progressively throughout the fatiguing 
contractions. Although the decreases were similar between sessions, it can still be 
concluded that the fatigue exhibited can be contributed to the peripheral mechanisms of 
fatigue. Further research and more advanced protocols are needed in order to truly assess 
the mechanisms of fatigue and the effect that supplementation with an Alpha-GPC 
supplement can have on fatigue.  
 Practical Application 
These findings suggest that it is possible to increase RFD with supplementation while not 
improving overall maximum strength. Athletes across a wide variety of team sports (ex. 
football, basketball, and hockey) could see improvements in performance by 
supplementation with Myosync™. Specifically, improved RFD will allow athletes to better 
withstand the unpredictable nature of sports such as being hit or having to change directions 
quickly. In addition to improving sports performance, athletes who are able to generate 
more force quickly could be at less risk of suffering a contact related injury. 
 Limitations and Future Direction 
One potential limitation with the current study is that no measurements of the amount of 
free choline levels in the subjects were taken during the control and experimental sessions. 
As mentioned before, many of the previous studies involving choline supplementation 
measured the amount of free choline to investigate if the supplement was effective at the 
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most basic level. Future research investigating the effect of Myosync™ or any form of 
choline supplementation would benefit from this measurement.  
 Another possible limitation within the current study is with the dosage of the 
supplement Myosync™. The manufacturers of Myosync™ recommend a dosage of two to 
four capsules, depending on the training level of the individual. For the simplicity of the 
current study, all subjects received only two capsules of Myosync™, which seemed to 
show improvements for some individuals while showing no effect for others. Future 
research involving supplementation and performance should take into effect dosage 
amounts for individual subjects as well as taking consideration of responders and non-
responders to the supplement.  
Assessing voluntary activation using electrical stimulation was difficult for both 
the experimenter as well as the subject. A possible better alternative method to assess 
voluntary activation going forward would be the use of magnetic stimulation. Magnetic 
stimulation is a less painful technique and could provide more accurate data concerning the 
integrity of the neuromuscular junction. In the future, using magnetic stimulation, which is 
generally a less painful technique, could be a good alternative for research regarding 
voluntary activation. 
The current research provides various implications for not only researchers and 
sports scientist, but also coaches and athletes as well. Many studies involving athletic 
performance have a major limitation within their subject pool. When investigating 
athletic performance it is important to test trained athletes, and many studies involve 
“trained” college subjects. Based on the results of the current study, improvements in 
RFD can be seen with acute supplementation and are not only improved via strength 
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training. The current research involved many laboratory measurements that are not 
commonly utilized when studying athletic performance. In the future, it is imperative that 
athletes, coaches, and researchers work together when studying athletic performance to 
assess both practical measures and other more detailed measures assessed in a laboratory. 
6. CONCLUSION
Acute supplementation with Myosync™ did not have a significant effect on either maximal 
vertical jump height or maximal isometric strength of the knee extensor muscles. However, 
supplementation with Myosync™ maintained RFD and impulse during MVIC 
measurements throughout the fatiguing protocol. These results indicate that athletes across 
many team sports can benefit from supplementation of Myosync™. 
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Appendix A: Raw data 
Table 3. Maximum Vertical Jump Height (inches)
Session Subject Jump 1 Jump 2 Jump 3 
Control  1 21.5 23 24 
2 26.5 26.5 26.0 
3 25.5 25.5 26.5 
4 28.0 28.5 29.0 
5 28.5 29.0 29.0 
6 26.0 26.0 26.0 
7 28.5 30.0 32.5 
8 27.5 29.0 29.5 
9 23.0 24.5 24.5 
10 29.5 28.0 28.0 
11 26.5 26.5 27.5 
12 25.5 26.0 26.0 
13 32.0 32.5 30.5 
14 27.5 25.0 27.0 
Supplemental 1 23.5 23.5 24.0 
2 28.5 28.0 28.5 
3 25.5 27.0 27.0 
4 27.0 25.5 29.0 
5 28.0 29.0 29.0 
6 28 27.5 27.5 
7 30.5 32.5 33.5 
8 29.0 26.0 25.5 
9 22.0 22.5 24.0 
10 28.5 27.0 28.5 
11 26.0 26.5 27.0 
12 23.5 25.0 25.5 
13 31.0 30.5 30.5 
14 27.5 27.5 26.0 
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Table 4. MVIC during baseline, fatigue, and recovery (Nm)
Session Subject Baseline Fatigue 1 Fatigue 2 Fatigue 3 Fatigue 4 Recovery  (10 min) 
Control  1 323.3 303.51 250.99 235.94 238.44 295.59 
2 274.67 278.14 201.63 163.08 147.94 206.07 
3 305.35 267.69 223.65 213.64 210.88 280.56 
4 302.74 271.77 205.78 183.68 159.39 233.87 
5 254.32 210.82 205.21 179.55 142.33 210.28 
6 316.01 220.11 204.21 149.74 182.55 212.99 
7 337.83 222.68 167.00 148.95 147.10 242.95 
8 321.47 265.87 218.24 205.35 170.71 250.61 
9 263.24 304.27 233.22 185.12 139.03 150.97 
10 315.45 257.11 191.97 173.39 181.99 283.11 
11 201.58 222.17 171.38 172.96 165.77 217.67 
12 308.75 287.07 224.68 212.65 214.01 207.28 
13 401.78 253.84 156.53 151.46 127.18 251.21 
14 242.48 246.12 185.77 142.38 170.94 170.93 
Supplemental 1 310.03 280.05 237.12 249.32 262.60 286.93 
2 320.74 332.53 257.03 228.08 212.03 260.36 
3 297.33 261.03 235.89 229.33 220.04 257.46 
4 312.29 268.73 192.44 177.83 170.35 237.07 
5 274.05 256.25 208.76 168.46 143.30 215.05 
6 340.30 245.14 218.31 181.27 199.79 232.49 
7 304.62 236.11 186.09 184.14 192.52 250.18 
8 291.47 259.93 210.43 172.68 176.52 287.82 
9 184.47 266.58 122.36 125.82 110.26 153.22 
10 283.35 241.84 195.48 188.56 130.72 269.99 
11 199.12 262.88 197.50 150.16 169.52 183.17 
12 252.70 275.00 230.16 207.58 186.15 229.68 
13 488.88 265.95 243.92 165.18 189.97 287.35 
14 294.94 211.01 221.45 184.15 151.95 213.63 
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Table 5. Rate of Torque Development during baseline, fatigue and recovery (Nm/s) 
Session Subject Baseline Fatigue 1 Fatigue 2 Fatigue 3 Fatigue 4 Recovery (10 min) 
Control  1 1843.40 1662.30 1246.30 1534.60 1390.30 2271.60 
2 2710.90 2487.20 1879.40 1453.60 1320.60 2787.90 
3 2743.20 2029.00 1656.00 1783.20 1739.30 3349.90 
4 2509.40 1601.00 1238.60 1013.40 880.90 1977.20 
5 916.50 1189.00 1323.50 871.70 1033.00 1517.40 
6 2938.20 2600.10 1998.90 857.50 1747.60 1736.70 
7 2433.90 1421.30 1101.20 1263.10 724.40 1560.40 
8 2108.50 1814.40 1585.90 1280.40 846.60 1644.50 
9 2039.30 2048.20 1897.40 1617.00 1008.10 1836.20 
10 2197.40 1456.90 1608.80 1010.40 1112.10 2237.20 
11 1711.90 1610.90 1134.40 1195.40 946.30 1893.90 
12 2157.60 2681.30 1744.80 1536.20 1298.80 1741.90 
13 2676.90 1289.10 860.30 911.10 502.80 1057.40 
14 1409.50 1993.10 1540.70 1434.50 1530.70 1008.20 
Supplemental 1 1954.20 2029.20 1416.40 1420.20 1856.80 1892.70 
2 2355.70 2921.20 1775.90 1965.60 2017.20 1899.30 
3 2204.20 2622.70 2305.10 2019.90 2242.50 2446.90 
4 2954.40 2166.40 1121.90 1079.60 1123.70 2149.60 
5 1059.20 1838.80 1231.50 1024.50 762.80 800.40 
6 2501.70 2980.20 1702.50 1839.80 1568.80 1980.90 
7 2047.60 1988.40 1470.40 1526.30 2182.60 2613.70 
8 1441.20 1814.70 2349.40 1193.30 1482.20 1900.60 
9 2157.50 2572.10 1823.90 1737.30 1450.60 2106.90 
10 2525.30 1590.60 1161.10 1193.90 1127.50 2493.10 
11 1804.90 2583.20 1409.10 1061.60 1186.70 1152.00 
12 2017.70 1624.80 1458.20 947.30 959.50 1860.20 
13 3276.50 2391.60 1987.90 950.10 1181.70 1776.60 
14 1883.40 2299.60 1573.20 1359.00 1233.50 2044.80 
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Table 6. Impulse 200 ms data at baseline, throughout fatigue, and recovery. (N/s) 
Session Subject Baseline Fatigue 1 Fatigue 2 Fatigue 3 Fatigue 4 Recovery (10 min) 
Control  1 26.80 22.55 18.26 18.27 13.44 25.13 
2 32.39 34.54 19.70 17.02 14.42 19.99 
3 33.68 24.99 21.95 20.38 18.13 34.62 
4 31.56 20.06 10.90 16.26 12.88 26.20 
5 13.87 11.48 15.16 11.91 1.79 21.42 
6 25.94 23.68 19.98 9.59 16.77 18.71 
7 30.27 21.73 11.32 13.46 11.08 19.48 
8 28.12 23.05 18.96 17.61 13.78 21.60 
9 24.88 15.49 17.28 11.91 12.26 18.28 
10 28.60 13.87 14.43 8.90 15.22 26.88 
11 19.95 15.63 16.19 15.45 15.98 23.79 
12 31.03 25.79 14.25 11.72 14.63 23.27 
13 36.84 19.64 12.64 12.81 6.50 18.17 
14 16.59 21.22 18.37 11.94 15.52 14.43 
Supplemental 1 29.31 24.89 16.36 19.20 17.64 25.68 
2 28.81 35.31 23.82 23.81 19.22 16.34 
3 30.21 28.70 25.39 25.40 23.72 31.52 
4 36.75 24.20 15.42 13.15 14.91 29.28 
5 14.45 20.35 12.52 13.41 9.67 7.88 
6 31.45 25.34 19.22 15.65 16.91 20.14 
7 28.53 25.14 14.99 19.07 3.77 29.59 
8 23.42 23.08 22.12 19.11 17.94 24.23 
9 25.30 24.49 16.79 16.36 13.00 20.75 
10 30.58 21.53 11.35 6.15 11.05 28.37 
11 22.03 25.13 18.61 9.26 12.05 14.96 
12 28.05 23.20 18.54 14.16 14.48 21.69 
13 45.28 20.33 17.76 13.53 15.91 25.04 
14 24.90 20.93 20.13 17.84 9.70 17.56 
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Table 7. Resting twitch torque data at baseline, throughout fatigue, and recovery. (Nm) 
Session Subject Baseline Fatigue 1 Fatigue 2 Fatigue 3 Fatigue 4 Recovery (10 min) 
Control  1 89.11 76.21 50.73 45.96 46.96 71.48 
2 108.45 67.78 41.21 37.52 34.39 95.12 
3 72.33 45.1 28.26 21.75 27.04 59.33 
4 72.69 40.65 29.99 24.5 20.02 40.44 
5 52.77 37.12 23.25 17.91 13.12 34.8 
6 73 60.95 46.46 42.89 41.05 53.89 
7 74.39 39.28 26.29 30.73 29.44 50.53 
8 73.71 44.26 34.25 29.62 28.45 51.73 
9 72.47 64.05 34.91 31.3 25.23 44.57 
10 56.61 21.22 16.4 14.83 18.98 38.61 
11 82.2 55.36 40.44 37.61 29.07 62.86 
12 83.89 53.72 21.17 19.17 13.39 47.24 
13 72.43 39.23 18.82 18.02 29.22 42.22 
14 66.33 48.46 32.24 21.99 22.45 45.85 
Supplemental 1 82.75 59.29 48.74 43.1 56.56 76 
2 106.95 62.34 41.32 51.91 38.98 89.03 
3 74.41 50.15 37.67 41.38 33.47 42.44 
4 56.88 38.12 21.04 18.66 19.03 35.07 
5 68.84 34.94 28.05 20.81 14.83 36.84 
6 88.95 60.85 38.3 34.37 37.58 55.76 
7 82.79 55.57 41 32.79 28.9 56.67 
8 68.02 46.97 44.74 52.02 37.26 50.63 
9 67 62.78 43.9 36.66 32.6 49.93 
10 67.62 28.92 18.23 17.19 16.78 43.3 
11 77.08 65.65 56.09 41.53 35.99 56.55 
12 69.81 39.34 21.35 16.96 19.49 47.29 
13 97.73 41.31 26.63 23.41 22.48 53.09 
14 49.46 38.53 29.9 18.53 15.71 40.08 
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Table 8. Voluntary Activation data at baseline, throughout fatigue, and recovery. (%) 
Session Subject Baseline Fatigue 1 Fatigue 2 Fatigue 3 Fatigue 4 Recovery (10 min) 
Control  1 91.28 92.8 92.13 91.03 88.94 86.58 
2 82.76 99.06 96.82 93.16 90.49 80.73 
3 79.61 100 94.11 99.99 99.99 85.48 
4 96.77 95.59 74.22 93.94 99.99 100 
5 100 71.45 87.92 86.53 74.47 100 
6 88.21 93.52 75.1 74.38 79.94 69.09 
7 100 73.88 83.27 91.38 93.53 88.42 
8 95.56 97.32 88.34 99.99 84.08 85.9 
9 79.92 100 62.94 100 99.99 83.42 
10 100 86.9 99.71 86.07 97.13 68.5 
11 68.37 95.28 82.92 100 99.99 66.62 
12 86.53 98.31 97.45 99.99 95.53 86.41 
13 100 84.8 77.28 88.73 54.93 84.62 
14 89.48 93.99 100 99.44 88.26 100 
Supplemental 1 88.43 91.42 95.3 100 87.08 72.88 
2 81.82 96 92.52 78.33 79.69 84.57 
3 95.19 85.51 100 99.43 96.36 85.27 
4 87.03 97.58 87.86 78.6 85.95 100 
5 95.1 100 90.75 77.9 99.99 71.51 
6 84.09 88.05 92.91 77.52 91.99 89.79 
7 93.9 79.38 83.49 73.52 78.51 92.49 
8 88.45 87.31 93.91 70.51 81.27 97.34 
9 67.16 86.37 86.11 77.79 70.96 64.12 
10 84.21 99.99 99.99 99.99 99.49 96.41 
11 70.84 95.24 91.63 56.58 86.29 82.5 
12 80.48 100 94.66 99.99 99.99 79.98 
13 100 65.94 91.04 89.23 75.31 93.86 
14 100 85.98 -16.12 83.39 9.49 69.55 
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Table 9. Corrected Voluntary Activation data at baseline, throughout fatigue, and 
recovery. (%) 
Session Subject Baseline Fatigue 1 Fatigue 2 Fatigue 3 Fatigue 4 Recovery (10 min) 
Control  1 99.8 99.89 99.55 99.86 99.77 99.25 
2 98.43 99.89 99.47 98.47 98.81 96.81 
3 98.77 100 99.04 100 100 99.6 
4 99.96 99.97 99.06 99.92 100 100 
5 100 96.82 98.17 99.07 98.58 100 
6 99.52 99.11 94.67 95.18 94.67 91.84 
7 100 98.82 99.59 99.72 99.91 99.74 
8 99.89 99.81 99.51 100 97.13 98.7 
9 97.94 100 93.38 100 100 96.9 
10 100 98.2 99.96 99.51 99.28 92.16 
11 96.2 99.59 97.68 100 100 90.27 
12 99.13 99.94 99.88 100 99.89 97.5 
13 100 99.73 99.05 99.32 95.58 99.67 
14 99.69 99.49 100 99.95 98.29 100 
Supplemental 1 99.65 99.59 99.84 100 98.18 97.67 
2 98.99 99.69 99.58 97.54 97.93 98.51 
3 99.66 99.66 100 99.98 99.88 98.02 
4 99.71 99.99 99.87 99.56 99.84 100 
5 99.94 100 99.05 99.03 100 98.7 
6 99.35 98.7 98.99 99.14 99.81 99.77 
7 99.83 98.78 98.79 98.85 96.75 99.39 
8 99.4 98.06 99.14 90.32 97.77 99.73 
9 93.69 95.73 97.14 93.04 87.05 91.13 
10 98.38 100 100 100 99.91 99.72 
11 96.83 98.8 98.78 93.81 95.81 95.81 
12 98.41 100 99.94 100 100 94.55 
13 100 98.34 99.88 99.19 98.96 99.55 
14 100 99.32 70.17 99.72 91.83 96.82 
71 
Table 10. Peak Isotonic Power Baseline. (Watts) 
Session Subject 1 Nm 10% 20% 30% 40% 50% 
60% 
Control 1 418.1 609.1 533.8 499.1 442.6 451.9 482.9 
2 561.1 699.2 551.3 727 654.7 688.3 718.9 
3 707.3 523.2 559.2 537.2 534.1 489.6 438.8 
4 667.3 689.1 451.4 674.5 631.7 548.5 653.9 
5 449.5 511.8 591 534.4 507.9 408.8 632.8 
6 496.1 710.6 639.6 572.5 589.6 646.3 495.5 
7 628.4 412 637.4 656.7 501.7 563.7 476.7 
8 523.1 456.3 515.4 546.4 579.6 620.5 582.8 
9 497.7 479.2 423.6 630.8 470.8 594.2 554.7 
10 584.2 493.5 562.1 541.7 529.2 590 628.2 
11 604.4 600.1 510.7 561.6 600.6 625.3 685.4 
12 613.1 562.7 581.7 569.1 580.3 472.6 510.8 
13 458.9 738.2 723.6 735.1 703.1 738.9 643.6 
14 562.2 470.5 425.6 576.3 556.7 562.2 631.1 
Supplemental 1 316.2 527.3 430.2 494 496.3 515.2 496.6 
2 755.7 632.9 593.7 711.3 642.2 623.1 671.4 
3 693.4 607.2 590.4 487.4 624.2 630.1 544.6 
4 636.2 599.7 655.4 599 642.1 614.9 522.4 
5 470.9 444.1 427.3 514.4 430.8 445.9 456.2 
6 657.9 807.1 785.9 613.4 490.9 501.7 396.9 
7 558.5 443.1 450.7 567 522.1 560 521.6 
8 373.5 405.6 413 525 452.8 495 519 
9 585.5 444.8 589.6 650.8 513.2 626.2 509 
10 503.1 542.4 516.6 585.6 585.4 536 606 
11 589.9 605.5 395.9 473.2 525.4 510.2 567.4 
12 349.1 446 488 444.8 431.3 413.2 436.2 
13 819.5 726.8 718.3 647 672.5 770 589.6 
14 417.6 466.8 457.2 644.5 611.7 605.8 603.6 
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Table 11. Peak Isotonic Power Recovery. (Watts)  
Session Subject 1 Nm 10% 20% 30% 40% 50% 
60% 
Control 1 536.5 477.2 518.2 491.6 383.7 416.8 413.6 
2 662.5 525.1 628.2 663.4 615.7 595.8 626.2 
3 713.6 510.9 619.7 483 553.8 554.6 444.6 
4 520.1 463 530.2 477.6 525.7 541 503.6 
5 402.3 340.4 550.2 446.3 463 470.3 472.4 
6 468.7 555.7 440.1 557.7 478.4 484.7 388.7 
7 612.4 537.4 634.1 589.3 499 576.5 523.4 
8 414.5 474.5 601.7 466 479.7 587.5 486.2 
9 277 432.5 378.2 398.1 395.3 402.1 422.7 
10 530.8 400.1 458.2 520.2 565.8 561.2 534 
11 546.4 576.8 371.8 514.5 626 503.7 492.3 
12 458.7 436.8 340.3 343.5 367.7 412.8 351.1 
13 587.5 531.5 540.6 605.6 637.1 542.7 519.9 
14 546.2 581.2 461.3 435.8 641.8 531.6 560.4 
Supplemental 1 603.6 489 407.3 453.6 408.9 521.9 492.9 
2 734 596.3 502 602.3 584.4 559.8 600.6 
3 626.4 505.8 514.6 609.9 544 538.6 529.9 
4 384.1 499.3 487.6 568 561.9 492.6 553.3 
5 490.5 461 389.4 474.5 481.9 501 497.1 
6 477.6 420.8 642.3 473.6 402.4 378.8 325.2 
7 500.5 401.6 346.2 409.1 461.1 489.4 433.6 
8 246.9 274.7 275.6 288 464.6 524.3 372.5 
9 485.3 484.7 443.1 370.7 436.9 383.4 492.6 
10 530.3 523 429 479.2 530.3 545.1 529.6 
11 626.6 553.6 586.2 485.6 442.6 616 545.5 
12 404.9 361.2 429.7 334.2 313.8 374.1 337.4 
13 351.5 358.4 468.4 545.6 491.6 402.4 352.3 
14 581.2 664.3 553.2 476.3 459.2 510.6 536.1 
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Table 12. RMS EMG Activity during MVIC Rectus Femoris (mv) 
Session Subject Baseline Fatigue 1 Fatigue 2 Fatigue 3 Fatigue 4 Recovery (10 min) 
Control  1 0.196 0.170 0.141 0.151 0.108 0.163 
2 0.203 0.147 0.078 0.074 0.056 0.116 
3 0.530 0.399 0.192 0.204 0.186 0.594 
4 0.346 0.389 0.324 0.159 0.190 0.323 
5 0.432 0.265 0.172 0.214 0.211 0.274 
6 0.355 0.179 0.178 0.188 0.115 0.346 
7 0.485 0.552 0.332 0.254 0.386 0.527 
8 0.331 0.258 0.292 0.205 0.092 0.345 
9 0.173 0.137 0.071 0.064 0.051 0.080 
10 0.672 0.313 0.240 0.600 0.198 0.487 
11 0.208 0.122 0.075 0.099 0.110 0.156 
12 0.302 0.330 0.151 0.255 0.228 0.188 
13 0.550 0.327 0.158 0.179 0.175 0.596 
14 0.275 0.258 0.187 0.120 0.148 0.284 
Supplemental 1 0.2066 0.1645 0.1593 0.1358 0.1289 0.2823 
2 0.2321 0.1713 0.1425 0.0825 0.0892 0.1657 
3 0.4235 0.5155 0.433 0.3437 0.3699 0.5306 
4 0.3216 0.3365 0.2936 0.1868 0.2631 0.3636 
5 0.4492 0.2912 0.1732 0.1488 0.1203 0.4244 
6 0.4071 0.2815 0.2108 0.3232 0.2825 0.4563 
7 0.5877 0.5839 0.3865 0.4106 0.4439 0.4529 
8 0.4024 0.4419 0.1324 0.0712 0.1257 0.4097 
9 0.1085 0.0704 0.0424 0.0464 0.0428 0.0751 
10 0.4808 0.2285 0.2459 0.2154 0.0671 0.5351 
11 0.1661 0.1768 0.1196 0.0846 0.0683 0.1705 
12 0.2021 0.1691 0.1619 0.0909 0.0971 0.1393 
13 0.6404 0.4559 0.3342 0.1536 0.3329 0.467 
14 0.3474 0.2023 0.2735 0.2033 0.234 0.2725 
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Table 13. RMS EMG Activity during MVIC for Vastus Medialis (mv) 
Session Subject Baseline Fatigue 1 Fatigue 2 Fatigue 3 Fatigue 4 Recovery (10 min) 
Control  1 0.4072 0.4068 0.317 0.3496 0.4975 0.4623 
2 0.2038 0.1403 0.087 0.1044 0.0853 0.194 
3 0.8389 0.7634 0.3975 0.3806 0.4489 0.8736 
4 1.062 1.5294 1.0989 0.85 1.0266 1.4813 
5 0.8764 0.5594 0.6972 0.6661 0.7421 0.8067 
6 1.3143 0.5156 0.6558 0.4083 0.4883 0.6525 
7 1.5485 1.0857 1.0493 0.6794 1.1146 1.5501 
8 1.0782 0.7497 0.7075 0.5432 0.4101 0.6545 
9 0.5373 0.4553 0.2905 0.1713 0.136 0.1321 
10 1.0194 0.6895 0.4019 0.568 0.274 0.8017 
11 0.2984 0.2409 0.2067 0.167 0.1947 0.2755 
12 0.5591 0.5872 0.3503 0.4746 0.5229 0.4921 
13 1.3506 0.9204 0.4918 0.463 0.4857 0.957 
14 0.5003 0.5289 0.2535 0.2936 0.2537 0.3697 
Supplemental 1 0.2598 0.2266 0.2661 0.2291 0.1397 0.2602 
2 0.4672 0.4141 0.3122 0.2188 0.3271 0.3565 
3 0.8707 1.2121 1.0129 0.9384 0.9645 0.856 
4 0.7138 0.6291 0.6897 0.4852 0.4349 0.8279 
5 1.0031 0.7064 0.5153 0.5025 0.3962 1.4412 
6 1.1999 0.6137 0.3308 0.5511 0.7103 0.9509 
7 1.1529 1.2531 0.9384 0.8674 0.8049 1.1198 
8 0.595 0.35 0.2446 0.1042 0.2853 0.4715 
9 0.4927 0.259 0.113 0.1071 0.19 0.2729 
10 1.0618 0.4856 0.4637 0.5679 0.2494 1.0387 
11 0.2471 0.1684 0.1641 0.1503 0.1786 0.2323 
12 0.2844 0.2253 0.2753 0.2109 0.158 0.2258 
13 1.4552 0.9085 1.2874 0.3736 0.9528 0.9753 
14 0.673 0.4016 0.5475 0.4845 0.4546 0.7038 
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Table 14. RMS EMG Activity during MVIC for Vastus Lateralis. (mv) 
Session Subject Baseline Fatigue 1 Fatigue 2 Fatigue 3 Fatigue 4 Recovery (10 min) 
Control  1 0.2552 0.2591 0.2137 0.2127 0.1908 0.2049 
2 0.3181 0.3427 0.163 0.107 0.1199 0.2759 
3 0.7823 0.67 0.3911 0.32 0.5021 1.0797 
4 0.7076 0.8082 0.8125 0.4731 0.7096 0.8188 
5 0.5433 0.4509 0.4559 0.4181 0.2831 0.4721 
6 0.5059 0.2854 0.284 0.2712 0.2271 0.3763 
7 1.0916 0.843 0.6535 0.7347 0.7758 1.2286 
8 0.3222 0.257 0.2649 0.2208 0.1489 0.3604 
9 0.19 0.1661 0.0949 0.0674 0.0642 0.0942 
10 0.8357 0.5699 0.3841 0.6039 0.2866 0.7278 
11 0.1183 0.5137 0.0832 0.0736 0.0931 0.1213 
12 0.2513 0.2823 0.1485 0.3058 0.2439 0.2005 
13 0.5909 0.4786 0.3478 0.3829 0.3111 0.8001 
14 0.4691 0.456 0.3025 0.1989 0.3693 0.61 
Supplemental 1 0.3608 0.3078 0.3182 0.2456 0.2417 0.3038 
2 0.2155 0.1754 0.1513 0.1415 0.1224 0.2549 
3 0.4276 0.4162 0.3153 0.3193 0.3878 0.3805 
4 0.6449 0.6146 0.641 0.4856 0.5689 0.9615 
5 0.5978 0.4987 0.3923 0.4558 0.3446 0.4573 
6 0.4661 0.2612 0.2586 0.3189 0.3878 0.5926 
7 0.7191 0.7304 0.5651 0.6646 0.7469 0.808 
8 0.3822 0.2687 0.2627 0.0954 0.2043 0.4378 
9 0.1615 0.0942 0.0413 0.0478 0.0451 0.107 
10 0.7787 0.6322 0.5259 0.4785 0.1656 0.575 
11 0.2854 0.1991 0.229 0.2005 0.1638 0.3155 
12 0.3651 0.3323 0.4556 0.2729 0.2404 0.2982 
13 0.8795 0.7199 0.654 0.3467 0.5784 0.8779 
14 0.6618 0.4511 0.6007 0.5067 0.5988 0.8687 
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Appendix B: Statistics 
Table 15. Mean data for MVIC Measures (Nm). 
MVIC  Session N Mean Std.  Dev. Std. Error 
Baseline    Control 14 297.79 56.56 15.12 
Supplemental 14 296.73 79.14 21.15 
Fatigue 1  Control 14 257.94 30.58 8.17 
Supplemental 14 261.65 27.10 7.24 
Fatigue 2  Control 14 202.88 26.65 7.12 
Supplemental  14 211.21 33.15 8.86 
Fatigue 3 Control 14 179.85 28.42 7.59 
Supplemental 14 186.61 32.87 8.78 
Fatigue 4 Control 14 171.30 31.95 8.54 
Supplemental 14 179.69 39.00 10.42 
Recovery (10 min) Control 14 229.58 41.50 11.09 
Supplemental  14 240.32 39.91 10.67 
Table 16. T-test for Baseline MVIC 
Paired Differences 
Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
t df Sig.(2-
tailed) 
Lower Upper 
Baseline 
Control vs 
Supplemental 
Session 
1.05 44.84 11.98 -24.84 26.94 .088 13 .931 
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Table 17. Repeated Measure Tests of Within-Subjects Effects MVIC during fatiguing 
task (control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 956.515 1 956.515 .426 .525 .032 
Greenhouse-Geisser 956.515 1 956.515 .426 .525 .032 
Huynh-Feldt 956.515 1 956.515 .426 .525 .032 
Lower-bound 956.515 1 956.515 .426 .525 .032 
Session*Rep Sphericity Assumed 446.339 4 111.585 .356 .839 .027 
Greenhouse-Geisser 446.339 1.565 134.436 .356 .805 .027 
Huynh-Feldt 446.339 1.741 111.585 .356 .839 .027 
Lower-bound 446.339 1.000 446.339 .356 .561 .027 
Error(Session*Rep) Sphericity Assumed 16317.564 52 317.799 
Greenhouse-Geisser 16317.564 43.161 378.061 
Huynh-Feldt 16317.564 52.000 313.799 
Lower-bound 16317.564 13.000 1255.197 
Table 18. Repeated Measure Tests of Within-Subjects Effects MVIC Recovery (fatigue 4 
vs. recovery; control vs. supplemental). 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 1280.371 1 1280.371 2.100 .171 .139 
Greenhouse-Geisser 1280.371 1 1280.371 2.100 .171 .139 
Huynh-Feldt 1280.371 1 1280.371 2.100 .171 .139 
Lower-bound 1280.371 1 1280.371 2.100 .171 .139 
Session*Rep Sphericity Assumed 19.270 1 19.270 .064 0.804 .005 
Greenhouse-Geisser 19.270 1 19.270 .064 0.804 .005 
Huynh-Feldt 19.270 1 19.270 .064 0.804 .005 
Lower-bound 19.270 1 19.270 .064 0.804 .005 
Error(Session*Rep) Sphericity Assumed 3895.923 13 299.686 
Greenhouse-Geisser 3895.923 13 299.686 
Huynh-Feldt 3895.923 13 299.686 
Lower-bound 3895.923 13 299.686 
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Table 19. Mean Data for RTD (Nm/s) 
MVIC  Session N Mean Std.  Dev. Std. Error 
Baseline  Control 14 2171.19 564.39 150.84 
Supplemental 14 2155.96 566.65 151.44 
Fatigue 1  Control 14 1848.84 480.15 128.32 
Supplemental 14 2244.54 453.02 121.07 
Fatigue 2  Control 14 1486.87 341.86 91.37 
Supplemental  14 1627.61 387.79 103.64 
Fatigue 3 Control 14 1268.72 301.53 80.59 
Supplemental 14 1379.89 379.72 101.49 
Fatigue 4 Control 14 1148.68 372.05 99.44 
Supplemental 14 1455.44 462.29 123.55 
Recovery (10 min) Control 14 1901.46 622.42 166.35 
Supplemental  14 1936.98 485.10 129.65 
Table 20. T-test for Baseline RTD 
Paired Differences 
Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence Interval 
of the Difference 
t df Sig.(2-
tailed) 
Lower Upper 
Baseline 
Control vs 
Supplemental 
Session 
15.22 407.90 109.02 -220.29 250.74 .140 13 .891 
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Table 21. Repeated Measure Tests of Within-Subjects Effects RTD during fatiguing task 
(control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 1234747 1 1234747 7.392 .018 .363 
Greenhouse-Geisser 1234747 1.000 1234747 7.392 .018 .363 
Huynh-Feldt 1234747 1.000 1234747 7.392 .018 .363 
Lower-bound 1234747 1.000 1234747 7.392 .018 .363 
Session*Rep Sphericity Assumed 746732.1 4 186683.0 2.226 .079 .146 
Greenhouse-Geisser 746732.1 3.154 236754.7 2.226 .079 .146 
Huynh-Feldt 746732.1 4.000 186683.0 2.226 .079 .146 
Lower-bound 746732.1 1.000 746732.1 2.226 .079 .146 
Error(Session*Rep) Sphericity Assumed 4361355 52 83872.2 
Greenhouse-Geisser 4361355 41.002 106368.2 
Huynh-Feldt 4361355 52.000 83872.2 
Lower-bound 4361355 13.000 335488.9 
Table 22. Repeated Measure Tests of Within-Subjects Effects RTD during Recovery 
(fatigue 4 vs. recovery; control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 410041.2 1 410041.2 2.090 .172 .138 
Greenhouse-Geisser 410041.2 1.000 410041.2 2.090 .172 .138 
Huynh-Feldt 410041.2 1.000 410041.2 2.090 .172 .138 
Lower-bound 410041.2 1.000 410041.2 2.090 .172 .138 
Session*Rep Sphericity Assumed 257490.8 1 257490.8 1.693 .216 .115 
Greenhouse-Geisser 257490.8 1.000 257490.8 1.693 .216 .115 
Huynh-Feldt 257490.8 1.000 257490.8 1.693 .216 .115 
Lower-bound 257490.8 1.000 257490.8 1.693 .216 .115 
Error(Session*Rep) Sphericity Assumed 1977197 13 152092.1 
Greenhouse-Geisser 1977197 13.000 152092.1 
Huynh-Feldt 1977197 13.000 152092.1 
Lower-bound 1977197 13.000 152092.1 
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Table 23. Mean Data for Impulse 200 ms (Ns) 
MVIC  Session N Mean Std.  Dev. Std. Error 
Baseline  Control 14 27.18 5.79 1.75 
Supplemental 14 26.13 6.74 1.80 
Fatigue 1  Control 14 20.76 5.79 1.55 
Supplemental 14 25.10 4.67 1.25 
Fatigue 2  Control 14 16.68 3.51 0.94 
Supplemental  14 18.20 4.13 1.10 
Fatigue 3 Control 14 14.41 2.96 0.79 
Supplemental 14 16.69 5.15 1.38 
Fatigue 4 Control 14 13.83 3.92 1.05 
Supplemental 14 14.51 4.69 1.25 
Recovery (10 min) Control 14 22.53 4.82 1.29 
Supplemental  14 23.21 5.97 1.59 
Table 24. T-test for Baseline Impulse 200 ms 
Paired Differences 
Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence Interval 
of the Difference 
t df Sig.(2-
tailed) 
Lower Upper 
Baseline 
Control vs 
Supplemental 
Session 
-1.32 4.36 1.16 -3.84 1.19 -1.14 13 0.276 
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Table 25. Repeated Measure Tests of Within-Subjects Effects Impulse during fatiguing 
task (control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 135.08 1 135.08 28.94 .000 .690 
Greenhouse-Geisser 135.08 1 135.08 28.94 .000 .690 
Huynh-Feldt 135.08 1 135.08 28.94 .000 .690 
Lower-bound 135.08 1 135.08 28.94 .000 .690 
Session*Rep Sphericity Assumed 23.34 4 5.84 0.623 0.648 0.046 
Greenhouse-Geisser 23.34 3.541 6.59 0.623 0.629 0.046 
Huynh-Feldt 23.34 4.000 5.84 0.623 0.648 0.046 
Lower-bound 23.34 1.000 23.34 0.623 0.444 0.046 
Error(Session*Rep) Sphericity Assumed 486.94 52 9.36 
Greenhouse-Geisser 486.94 46.03 10.58 
Huynh-Feldt 486.94 52.00 9.36 
Lower-bound 486.94 13.000 37.48 
Table 26. Repeated Measure Tests of Within-Subjects Effects Impulse during Recovery 
(fatigue 4 vs. recovery; control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 6.20 1 6.20 0.56 0.468 0.041 
Greenhouse-Geisser 6.20 1 6.20 0.56 0.468 0.041 
Huynh-Feldt 6.20 1 6.20 0.56 0.468 0.041 
Lower-bound 6.20 1 6.20 0.56 0.468 0.041 
Session*Rep Sphericity Assumed 4.87 1 4.87 0.24 0.63 .115 
Greenhouse-Geisser 4.87 1 4.87 0.24 0.63 .115 
Huynh-Feldt 4.87 1 4.87 0.24 0.63 .115 
Lower-bound 4.87 1 4.87 0.24 0.63 .115 
Error(Session*Rep) Sphericity Assumed 1977197 13 152092.1 
Greenhouse-Geisser 1977197 13.000 152092.1 
Huynh-Feldt 1977197 13.000 152092.1 
Lower-bound 1977197 13.000 152092.1 
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Table 27. Mean Data for Resting Twitch Torque (Nm) 
MVIC  Session N Mean Std.  Dev. Std. Error 
Baseline  Control 14 75.03 13.55 3.62 
Supplemental 14 75.59 15.36 4.10 
Fatigue 1  Control 14 49.53 14.50 3.87 
Supplemental 14 48.91 12.16 3.25 
Fatigue 2  Control 14 31.74 10.34 2.76 
Supplemental  14 35.50 11.45 3.10 
Fatigue 3 Control 14 28.13 9.95 2.66 
Supplemental 14 32.09 12.80 3.42 
Fatigue 4 Control 14 27.06 9.54 2.55 
Supplemental 14 29.26 11.90 3.18 
Recovery (10 min) Control 14 52.76 15.76 4.21 
Supplemental  14 52.33 14.83 3.96 
Table 28. T-test for Baseline Resting Twitch 
Paired Differences 
Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
t df Sig.(2-
tailed) 
Lower Upper 
Baseline 
Control vs 
Supplemental 
Session 
-0.57 13.03 3.48 -8.09 6.96 -0.16 13 0.874 
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Table 29. Repeated Measure Tests of Within-Subjects Effects Resting Twitch Torque 
during fatiguing task (control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 136.40 1 136.40 1.64 0.22 0.11 
Greenhouse-Geisser 136.40 1 136.40 1.64 0.22 0.11 
Huynh-Feldt 136.40 1 136.40 1.64 0.22 0.11 
Lower-bound 136.40 1 136.40 1.64 0.22 0.11 
Session*Rep Sphericity Assumed 111.16 4 27.79 0.84 0.51 0.06 
Greenhouse-Geisser 111.16 2.30 48.45 0.84 0.46 0.06 
Huynh-Feldt 111.16 2.81 39.50 0.84 0.48 0.06 
Lower-bound 111.16 1 111.16 0.84 0.38 0.06 
Error(Session*Rep) Sphericity Assumed 1723.90 52 33.15 
Greenhouse-Geisser 1723.90 29.83 57.78 
Huynh-Feldt 1723.90 36.59 47.12 
Lower-bound 1723.90 13 132.61 
Table 30. Repeated Measure Tests of Within-Subjects Effects Resting Twitch Torque 
during Recovery (fatigue 4 vs. recovery; control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 11.04 1 11.04 0.72 0.41 0.05 
Greenhouse-Geisser 11.04 1 11.04 0.72 0.41 0.05 
Huynh-Feldt 11.04 1 11.04 0.72 0.41 0.05 
Lower-bound 11.04 1 11.04 0.72 0.41 0.05 
Session*Rep Sphericity Assumed 24.24 1 24.24 0.93 0.35 0.07 
Greenhouse-Geisser 24.24 1 24.24 0.93 0.35 0.07 
Huynh-Feldt 24.24 1 24.24 0.93 0.35 0.07 
Lower-bound 24.24 1 24.24 0.93 0.35 0.07 
Error(Session*Rep) Sphericity Assumed 337.90 13 25.99 
Greenhouse-Geisser 337.90 13 25.99 
Huynh-Feldt 337.90 13 25.99 
Lower-bound 337.90 13 25.99 
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Table 31. Mean Data for Corrected Voluntary Activation (%) 
MVIC  Session N Mean Std.  Dev. Std. Error 
Baseline  Control 14 99.24 1.10 0.29 
Supplemental 14 98.85 1.72 0.46 
Fatigue 1  Control 14 99.38 1.28 0.24 
Supplemental 14 99.05 1.16 0.31 
Fatigue 2  Control 14 98.50 2.02 0.54 
Supplemental  14 97.23 7.83 2.09 
Fatigue 3 Control 14 99.36 1.28 0.34 
Supplemental 14 97.87 3.12 0.84 
Fatigue 4 Control 14 98.71 1.75 0.47 
Supplemental 14 97.41 3.74 1.00 
Recovery (10 min) Control 14 97.32 3.40 0.91 
Supplemental  14 97.81 2.53 0.68 
Table 32. T-test for Baseline Corrected Voluntary Activation 
Paired Differences 
Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
t df Sig.(2-
tailed) 
Lower Upper 
Baseline 
Control vs 
Supplemental 
Session 
0.39 1.27 0.34 -0.34 1.13 1.15 13 0.27 
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Table 33. Repeated Measure Tests of Within-Subjects Effects Corrected Voluntary 
Activation during fatiguing task (control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 32.01 1.00 32.01 2.01 0.18 0.13 
Greenhouse-Geisser 32.01 1.00 32.01 2.01 0.18 0.13 
Huynh-Feldt 32.01 1.00 32.01 2.01 0.18 0.13 
Lower-bound 32.01 1.00 32.01 2.01 0.18 0.13 
Session*Rep Sphericity Assumed 8.49 4.00 2.12 0.23 0.92 0.02 
Greenhouse-Geisser 8.49 1.57 5.42 0.23 0.75 0.02 
Huynh-Feldt 8.49 1.74 4.87 0.23 0.77 0.02 
Lower-bound 8.49 1.00 8.49 0.23 0.64 0.02 
Error(Session*Rep) Sphericity Assumed 486.25 52.00 9.35 
Greenhouse-Geisser 486.25 20.37 23.87 
Huynh-Feldt 486.25 22.67 21.45 
Lower-bound 486.25 13.00 37.40 
Table 34. Repeated Measure Tests of Within-Subjects Effects Corrected Voluntary 
Activation during Recovery (fatigue 4 vs. recovery; control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 2.26 1.00 2.26 0.16 0.69 0.01 
Greenhouse-Geisser 2.26 1.00 2.26 0.16 0.69 0.01 
Huynh-Feldt 2.26 1.00 2.26 0.16 0.69 0.01 
Lower-bound 2.26 1.00 2.26 0.16 0.69 0.01 
Session*Rep Sphericity Assumed 11.27 1.00 11.27 2.74 0.12 0.17 
Greenhouse-Geisser 11.27 1.00 11.27 2.74 0.12 0.17 
Huynh-Feldt 11.27 1.00 11.27 2.74 0.12 0.17 
Lower-bound 11.27 1.00 11.27 2.74 0.12 0.17 
Error(Session*Rep) Sphericity Assumed 53.40 13.00 4.11 
Greenhouse-Geisser 53.40 13.00 4.11 
Huynh-Feldt 53.40 13.00 4.11 
Lower-bound 53.40 13.00 4.11 
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Table 35. Mean Data for Peak Isotonic Power Baseline Measurements (Watts)  
MVIC  Session N Mean Std.  Dev. Std. Error 
1 Nm  Control 14 555.10 85.41 22.83 
Supplemental 14 551.93 154.33 41.25 
10%  Control 14 568.25 107.00 28.60 
Supplemental 14 549.95 119.59 31.96 
20% Control 14 550.46 84.53 22.59 
Supplemental  14 536.59 121.85 32.57 
30% Control 14 597.31 74.65 19.95 
Supplemental 14 568.39 80.23 21.44 
40% Control 14 563.04 71.93 19.22 
Supplemental 14 545.78 82.82 22.13 
50% Control 14 571.49 92.55 24.74 
Supplemental  14 560.52 91.88 24.56 
60% Control 14 581.15 87.80 23.47 
Supplemental  14 531.46 73.43 19.62 
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Table 36. Mean Data for Peak Isotonic Power Recovery Measurements (Watts)  
MVIC  Session N Mean Std.  Dev. Std. Error 
1 Nm    Control 14 519.80 112.00 29.93 
Supplemental 14 503.10 128.38 34.31 
10%  Control 14 488.79 69.90 18.68 
Supplemental 14 470.98 102.21 27.32 
20% Control 14 505.20 99.12 26.49 
Supplemental  14 462.47 96.16 25.70 
30% Control 14 499.47 84.88 22.69 
Supplemental 14 469.33 95.35 25.48 
40% Control 14 516.62 94.63 25.29 
Supplemental 14 470.26 71.27 19.05 
50% Control 14 512.95 66.10 17.67 
Supplemental  14 488.43 75.29 20.12 
60% Control 14 481.36 72.80 19.46 
Supplemental  14 471.33 90.38 24.15 
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Table 37. Repeated Measures test of Within Subjects Effects for Peak Isotonic Power 
baseline and recovery.   
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 54612.76 1.00 54612.76 3.77 0.07 0.23 
Greenhouse-Geisser 54612.76 1.00 54612.76 3.77 0.07 0.23 
Huynh-Feldt 54612.76 1.00 54612.76 3.77 0.07 0.23 
Lower-bound 54612.76 1.00 54612.76 3.77 0.07 0.23 
Session*Intensity Sphericity Assumed 5820.30 6.00 970.05 0.22 0.97 0.02 
Greenhouse-Geisser 5820.30 2.55 2286.60 0.22 0.85 0.02 
Huynh-Feldt 5820.30 3.22 1809.07 0.22 0.89 0.02 
Lower-bound 5820.30 1.00 5820.30 0.22 0.64 0.02 
Error(Session*Intensity) Sphericity Assumed 338080.75 78.00 4334.37 
Greenhouse-Geisser 338080.75 33.09 10216.97 
Huynh-Feldt 338080.75 41.83 8083.26 
Lower-bound 338080.75 13.00 26006.21 
Session*Intensity*Time Sphericity Assumed 11607.09 6.00 1934.52 0.55 0.77 0.04 
Greenhouse-Geisser 11607.09 3.68 3154.75 0.55 0.69 0.04 
Huynh-Feldt 11607.09 5.31 2185.18 0.55 0.75 0.04 
Lower-bound 11607.09 1.00 11607.09 0.55 0.47 0.04 
Error(Session*Intensity*Time) Sphericity Assumed 273610.07 78.00 3507.82 
Greenhouse-Geisser 273610.07 47.83 5720.45 
Huynh-Feldt 273610.07 69.05 3962.34 
Lower-bound 273610.07 13.00 21046.93 
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Table 38. Mean Data for EMG RMS Rectus Femoris (mv) 
MVIC  Session N Mean Std.  Dev. Std. Error 
Baseline  Control 14 0.36 0.15 0.04 
Supplemental 14 0.36 0.16 0.04 
Fatigue 1  Control 14 0.27 0.12 0.03 
Supplemental 14 0.29 0.15 0.04 
Fatigue 2  Control 14 0.19 0.09 0.02 
Supplemental  14 0.22 0.11 0.03 
Fatigue 3 Control 14 0.20 0.13 0.03 
Supplemental 14 0.18 0.11 0.03 
Fatigue 4 Control 14 0.16 0.09 0.02 
Supplemental 14 0.19 0.13 0.03 
Recovery (10 min) Control 14 0.32 0.17 0.05 
Supplemental  14 0.34 0.15 0.04 
Table 39. Repeated Measure Tests of Within-Subjects Effects EMG Rectus Femoris 
during fatiguing task (control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 501.28 1.00 501.28 0.98 0.34 0.07 
Greenhouse-Geisser 501.28 1.00 501.28 0.98 0.34 0.07 
Huynh-Feldt 501.28 1.00 501.28 0.98 0.34 0.07 
Lower-bound 501.28 1.00 501.28 0.98 0.34 0.07 
Session*Rep Sphericity Assumed 836.28 4.00 209.07 1.08 0.38 0.08 
Greenhouse-Geisser 836.28 3.10 269.76 1.08 0.37 0.08 
Huynh-Feldt 836.28 4.00 209.07 1.08 0.38 0.08 
Lower-bound 836.28 1.00 836.28 1.08 0.32 0.08 
Error(Session*Rep) Sphericity Assumed 10074.88 52.00 193.75 
Greenhouse-Geisser 10074.88 40.30 249.99 
Huynh-Feldt 10074.88 52.00 193.75 
Lower-bound 10074.88 13.00 774.99 
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Table 40. Repeated Measure Tests of Within-Subjects Effects EMG Rectus Femoris 
during Recovery (fatigue 4 vs. recovery; control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 1119.38 1.00 1119.38 4.46 0.06 0.26 
Greenhouse-Geisser 1119.38 1.00 1119.38 4.46 0.06 0.26 
Huynh-Feldt 1119.38 1.00 1119.38 4.46 0.06 0.26 
Lower-bound 1119.38 1.00 1119.38 4.46 0.06 0.26 
Session*Rep Sphericity Assumed 39.22 1.00 39.22 0.11 0.74 0.01 
Greenhouse-Geisser 39.22 1.00 39.22 0.11 0.74 0.01 
Huynh-Feldt 39.22 1.00 39.22 0.11 0.74 0.01 
Lower-bound 39.22 1.00 39.22 0.11 0.74 0.01 
Error(Session*Rep) Sphericity Assumed 4512.12 13.00 347.09 
Greenhouse-Geisser 4512.12 13.00 347.09 
Huynh-Feldt 4512.12 13.00 347.09 
Lower-bound 4512.12 13.00 347.09 
Table 41. Mean Data for EMG RMS Vastus Medialis. (mv)   
MVIC  Session N Mean Std.  Dev. Std. Error 
Baseline  Control 14 0.83 0.42 0.11 
Supplemental 14 0.75 0.38 0.10 
Fatigue 1  Control 14 0.66 0.35 0.09 
Supplemental 14 0.56 0.35 0.09 
Fatigue 2  Control 14 0.50 0.30 0.08 
Supplemental  14 0.51 0.35 0.09 
Fatigue 3 Control 14 0.44 0.21 0.06 
Supplemental 14 0.41 0.27 0.07 
Fatigue 4 Control 14 0.48 0.31 0.08 
Supplemental 14 0.45 0.29 0.08 
Recovery (10 min) Control 14 0.69 0.43 0.12 
Supplemental  14 0.69 0.39 0.11 
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Table 42. Repeated Measure Tests of Within-Subjects Effects EMG Vastus Medialis 
during fatiguing task (control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 18.95 1.00 18.95 0.02 0.88 0.00 
Greenhouse-Geisser 18.95 1.00 18.95 0.02 0.88 0.00 
Huynh-Feldt 18.95 1.00 18.95 0.02 0.88 0.00 
Lower-bound 18.95 1.00 18.95 0.02 0.88 0.00 
Session*Rep Sphericity Assumed 1013.23 4.00 253.31 1.01 0.41 0.07 
Greenhouse-Geisser 1013.23 3.35 302.63 1.01 0.40 0.07 
Huynh-Feldt 1013.23 4.00 253.31 1.01 0.41 0.07 
Lower-bound 1013.23 1.00 1013.23 1.01 0.33 0.07 
Error(Session*Rep) Sphericity Assumed 13003.57 52.00 250.07 
Greenhouse-Geisser 13003.57 43.53 298.76 
Huynh-Feldt 13003.57 52.00 250.07 
Lower-bound 13003.57 13.00 1000.28 
Table 43. Repeated Measure Tests of Within-Subjects Effects EMG Vastus Medialis 
during Recovery (fatigue 4 vs. recovery; control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 165.50 1.00 165.50 0.37 0.55 0.03 
Greenhouse-Geisser 165.50 1.00 165.50 0.37 0.55 0.03 
Huynh-Feldt 165.50 1.00 165.50 0.37 0.55 0.03 
Lower-bound 165.50 1.00 165.50 0.37 0.55 0.03 
Session*Rep Sphericity Assumed 231.81 1.00 231.81 0.58 0.46 0.04 
Greenhouse-Geisser 231.81 1.00 231.81 0.58 0.46 0.04 
Huynh-Feldt 231.81 1.00 231.81 0.58 0.46 0.04 
Lower-bound 231.81 1.00 231.81 0.58 0.46 0.04 
Error(Session*Rep) Sphericity Assumed 5239.60 13.00 403.05 
Greenhouse-Geisser 5239.60 13.00 403.05 
Huynh-Feldt 5239.60 13.00 403.05 
Lower-bound 5239.60 13.00 403.05 
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Table 44. Mean Data for EMG RMS Vastus Lateralis. (mv)  
MVIC  Session N Mean Std.  Dev. Std. Error 
Baseline  Control 14 0.50 0.28 0.08 
Supplemental 14 0.50 0.22 0.06 
Fatigue 1  Control 14 0.46 0.21 0.06 
Supplemental 14 0.41 0.21 0.06 
Fatigue 2  Control 14 0.33 0.21 0.06 
Supplemental  14 0.39 0.19 0.05 
Fatigue 3 Control 14 0.31 0.20 0.05 
Supplemental 14 0.33 0.18 0.05 
Fatigue 4 Control 14 0.31 0.22 0.06 
Supplemental 14 0.34 0.21 0.06 
Recovery (10 min) Control 14 0.53 0.36 0.10 
Supplemental  14 0.52 0.27 0.07 
Table 45. Repeated Measure Tests of Within-Subjects Effects EMG Vastus Lateralis 
during fatiguing task (control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 488.06 1.00 488.06 0.38 0.55 0.03 
Greenhouse-Geisser 488.06 1.00 488.06 0.38 0.55 0.03 
Huynh-Feldt 488.06 1.00 488.06 0.38 0.55 0.03 
Lower-bound 488.06 1.00 488.06 0.38 0.55 0.03 
Session*Rep Sphericity Assumed 8004.35 4.00 2001.09 1.89 0.13 0.13 
Greenhouse-Geisser 8004.35 1.31 6130.91 1.89 0.19 0.13 
Huynh-Feldt 8004.35 1.39 5750.47 1.89 0.19 0.13 
Lower-bound 8004.35 1.00 8004.35 1.89 0.19 0.13 
Error(Session*Rep) Sphericity Assumed 55211.91 52.00 1061.77 
Greenhouse-Geisser 55211.91 16.97 3253.03 
Huynh-Feldt 55211.91 18.10 3051.17 
Lower-bound 55211.91 13.00 4247.07 
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Table 46. Repeated Measure Tests of Within-Subjects Effects EMG Rectus Lateralis 
during Recovery (fatigue 4 vs. recovery; control-supplemental session) 
Type III SS df MS F Sig. Ƞ2p 
Session Sphericity Assumed 203.54 1.00 203.54 0.72 0.41 0.05 
Greenhouse-Geisser 203.54 1.00 203.54 0.72 0.41 0.05 
Huynh-Feldt 203.54 1.00 203.54 0.72 0.41 0.05 
Lower-bound 203.54 1.00 203.54 0.72 0.41 0.05 
Session*Rep Sphericity Assumed 6.78 1.00 6.78 0.02 0.88 0.00 
Greenhouse-Geisser 6.78 1.00 6.78 0.02 0.88 0.00 
Huynh-Feldt 6.78 1.00 6.78 0.02 0.88 0.00 
Lower-bound 6.78 1.00 6.78 0.02 0.88 0.00 
Error(Session*Rep) Sphericity Assumed 3638.28 13.00 279.87 
Greenhouse-Geisser 3638.28 13.00 279.87 
Huynh-Feldt 3638.28 13.00 279.87 
Lower-bound 3638.28 13.00 279.87 
